

# Journal of Materials Chemistry B

Materials for biology and medicine

[rsc.li/materials-b](https://rsc.li/materials-b)



Themed issue: Emerging Investigators 2021

ISSN 2050-750X

**PAPER**

Amirali Popat *et al.*  
Engineering mesoporous silica nanoparticles towards oral  
delivery of vancomycin

Cite this: *J. Mater. Chem. B*, 2021,  
9, 7145

## Engineering mesoporous silica nanoparticles towards oral delivery of vancomycin†

John Ndayishimiye,<sup>ib</sup><sup>a</sup> Yuxue Cao,<sup>a</sup> Tushar Kumeria,<sup>ib</sup><sup>b</sup> Mark A. T. Blaskovich,<sup>ib</sup><sup>c</sup>  
James Robert Falconer<sup>a</sup> and Amirali Popat<sup>ib</sup><sup>\*ad</sup>

Vancomycin (Van) is a key antibiotic of choice for the treatment of systemic methicillin resistant *Staphylococcus aureus* (MRSA) infections. However, due to its poor membrane permeability, it is administered parenterally, adding to the cost and effort of treatment. The poor oral bioavailability of Van is mainly due to its physico-chemical properties that limit its paracellular and transcellular transport across gastrointestinal (GI) epithelium. Herein we report the development of silica nanoparticles (SNPs)-based formulations that are able to enhance the epithelial permeability of Van. We synthesized SNPs of different pore sizes (2 nm and 9 nm) and modified their surface charge and polarity by attaching different functional groups ( $-\text{NH}_2$ ,  $-\text{PO}_3$ , and  $-\text{CH}_3$ ). Van was loaded within these SNPs at a loading capacity in the range of ca. 18–29 wt%. The Van-loaded SNPs exhibited a controlled release behaviour when compared to un-encapsulated Van which showed rapid release due to its hydrophilic nature. Among Van-loaded SNPs, SNPs with large pores showed a prolonged release compared to SNPs with small pores while SNPs functionalised with  $-\text{CH}_3$  groups exhibited a slowest release among the functionalised SNPs. Importantly, Van-loaded SNPs, especially the large pore SNPs with negative charge, enhanced the permeability of Van across an epithelial cell monolayer (Caco-2 cell model) by up to 6-fold, with  $P_{\text{app}}$  values up to  $1.716 \times 10^{-5} \text{ cm s}^{-1}$  (vs.  $0.304 \times 10^{-5} \text{ cm s}^{-1}$  for un-encapsulated Van) after 3 h. The enhancement was dependent on both the type of SNPs and their surface functionalisation. The permeation enhancing effect of SNPs was due to its ability to transiently open the tight junctions measured by decrease in transepithelial resistance (TEER) which was reversible after 3 h. All in all, our data highlights the potential of SNPs (especially SNPs with large pores) for oral delivery of Van or other antimicrobial peptides.

Received 26th June 2021,  
Accepted 9th August 2021

DOI: 10.1039/d1tb01430g

rsc.li/materials-b

### 1. Introduction

Infectious diseases are among the leading causes of death globally and it is estimated that, based on current trends, infectious diseases would be the leading cause of death by 2050 – more than cancer or cardiovascular diseases.<sup>1</sup> Notably, *Staphylococcus aureus* causes a wide range of life threatening infections, ranging from skin and soft tissue infections to infective endocarditis and bloodstream infections.<sup>2</sup> Due to its tendency to develop resistance to conventional antibiotics such as penicillins, cephalosporins and other  $\beta$ -lactam antibiotics,

*S. aureus* has become increasingly challenging from a public health perspective.<sup>3,4</sup> These methicillin resistant *S. aureus* (MRSA) infections can become real medical emergencies and their treatment presents a major challenge to the public and medical community.<sup>5</sup>

Although there are several options for treating invasive MRSA infections, vancomycin‡ (Van) has continued to be the primary course of treatment for the last fifty years.<sup>6–8</sup> Van (Fig. S1, ESI†) is a tricyclic glycopeptide that acts by inhibiting the bacterial cell-wall synthesis by binding to the D-Ala-D-Ala terminal group of the growing peptidoglycan peptide chain.<sup>9</sup> Although Van has been the drug of choice for MRSA, it must be administered *via* the intravenous route for *S. aureus* systemic infections,<sup>10</sup> due to its physico-chemical properties and the complexity of GI epithelium.§<sup>10,11</sup> (Note that it is given orally for *C. difficile* infections, but this is essentially topical delivery as the infection is in the gut<sup>12,13</sup>). Van is a large molecule of

<sup>a</sup> School of Pharmacy, Pharmacy Australia Centre of Excellence,  
The University of Queensland, Brisbane, Queensland 4102, Australia.  
E-mail: a.popat@uq.edu.au

<sup>b</sup> School of Materials Science and Engineering, University of New South Wales,  
New South Wales, Australia

<sup>c</sup> Centre for Superbug Solutions, Institute for Molecular Bioscience,  
The University of Queensland, St. Lucia, Queensland 4072, Australia

<sup>d</sup> Mater Research Institute – The University of Queensland, Translational Research  
Institute, 37 Kent St, Woolloongabba, QLD 4102, Australia

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1tb01430g

‡ In this paper Vancomycin Hydrochloride is simply referred to as Vancomycin (Van).

§ The anatomy of GI epithelium and how it can be a physiological barrier for the permeation of macromolecules are detailed in ref. 11.

1485.7 Da,<sup>14</sup> which is substantially greater than 500 Da maximum suggested by Lipinski for oral drug delivery.<sup>15,16</sup> In addition Van is hydrophilic<sup>17</sup> and this makes it difficult to partition and permeate through the enterocytes and reach lamina propria for systemic circulation either *via* paracellular or transcellular routes.<sup>11</sup> Moreover, its hydrogen bond donor and hydrogen bond acceptor counts are 20 and 26, respectively,<sup>14</sup> and this again greatly violates the Lipinski's guidelines for oral drug delivery (no more than 5 and 10, respectively).<sup>15,16</sup>

From the drug delivery point of view, an oral Van therapy could provide many benefits compared to Van administration *via* injection. While it can be dependent on case by case basis (inappropriate for critically ill patients or patients who are unable to absorb oral medications), switching from IV to oral administration would enable the reduction of length of stay in a hospital and improve cost effectiveness.<sup>18,19</sup> Moreover, a fear of injections is real and prevalent across populations, sometimes even surpassing 80% prevalence in patients,<sup>20</sup> where approximately 20–30% of patients are further classified as suffering from needle phobia.<sup>21</sup> In addition, “red man” syndrome and “pain and spasm” syndrome are other adverse effects associated with Van IV infusion.<sup>22,23</sup>

Different delivery systems and approaches have been used to improve the permeability *via* GI epithelium and/or oral delivery of macromolecules.<sup>11,24,25</sup> These delivery systems include for instance (1) focusing on the colloidal level, where ileal, colonic, and rectal permeation of peptides are enhanced using emulsions with different excipients and compositions,<sup>11</sup> (2) using polymer-based carrier systems, where polymeric nanoparticles have been used to overcome the oral physiological barriers,<sup>26</sup> (3) using solid lipid nanoparticles to specifically improve the stability of drugs of peptide nature<sup>27</sup> and (4) incorporating mucus-penetrating agents<sup>28</sup> and/or permeation enhancers<sup>29</sup> into the carrier systems in order to enhance the penetration of drugs into intestinal lumen mucus layer and permeate through GI epithelium. Another emerging approach that has been used to improve permeability and oral delivery of biologics is the use of mesoporous silica nanoparticles<sup>30–32</sup> where the drug can be entrapped and/or adsorb in the pores of silica nanoparticles (SNPs) either by physisorption (due to weak van der Waals forces) or by electrostatic interactions.<sup>33</sup>

Regarding Van and SNPs, previous works have mainly focused on for example: (1) Van encapsulation and release and its antimicrobial activity where Van is either physically adsorbed or covalently bonded to SNPs,<sup>34,35</sup> (2) localised and sustained release of Van for treatment of infected bone defects, where a composite scaffold based on Van-loaded mesoporous SNPs was fabricated and studied,<sup>36</sup> and (3) covalently bonding van on mesoporous SNPs for selective recognition and killing of pathogenic Gram-positive bacteria over macrophage-like cells.<sup>37</sup> However, there is no study on the applicability of functionalised SNPs with tunable chemistry for enhancing Van release and permeability with the purpose of improving its oral bioavailability. Therefore, to the best of our knowledge, this is the first work focusing specifically on the possibility of

engineering and characterising SNPs with the purpose of controlling its release and improving the oral bioavailability.

SNPs possess many attractive characteristics, such as high surface area, abundant and tuneable porosity, tuneable particle size and morphology, tuneable surface charge and chemistry and good chemical and mechanical stability.<sup>32,38,39</sup> Here we thought that we can explore the possibility of tuning parameters such as pore size, and surface chemistry in order to improve the permeability and other characteristics of loaded Van. Starting by the pore size, it has been documented that the pore size of SNPs plays an important role in loading and release of drugs<sup>40</sup> although the literature is conflicting. For instance, some literatures say that SNPs with larger pores normally give higher drug loading and faster drug release in comparison to SNPs with small pores, which is often ascribed to a steric hindrance effect.<sup>40–44</sup> Other literatures say otherwise.<sup>45,46</sup> So, our first hypothesis was whether the change of pore size can have an impact on loading, release behaviour and permeability of Van.

Besides pore size, surface charge is another interesting parameter that should be taken into consideration. Here due to the presence of silanol groups on SNPs surfaces, it is possible to modify the SNPs surfaces with groups of various charges, which would consequently play a role in the release and permeability characteristics of a drug.<sup>40,47–49</sup> The impact of SNPs surface charge on the delivery of therapeutics has been studied.<sup>32,40,47,49–52</sup> For instance, studying the impact of different functional groups, although their study was not on Van, Lamson *et al.*<sup>30</sup> used SNPs with different sizes and charges for oral delivery of insulin. They discovered that the more negatively charged nanoparticles with smaller size enhanced the permeability of insulin *in vitro* and *in vivo*. Our preliminary experiments showed that un-functionalised SNPs are anionic but does the increase of negative charge, by functionalizing SNPs with more anionic phosphonate groups, increase the permeability of Van? What if we functionalize them with cationic groups? Do cationic characteristics of SNPs surfaces have an impact on the permeability of Van? Surface polarity of SNPs is another parameter that we considered while engineering the surface chemistry of the SNPs. SNPs surface's polarity plays a critical role especially when the drug is being delivered transcellularly.<sup>40,49,52</sup> It is possible to modify the SNPs surfaces with the introduction of groups with different polarity. In the literature for example, neutral and hydrophilic nanoparticles have shown the ability to permeate through the intestinal mucus layer,<sup>53</sup> whereas hydrophobic nanoparticles have been successful in epithelial transport.<sup>54</sup> Here, we hypothesized that the functionalisation of SNPs with hydrophobic groups would affect the release behaviour, permeability, and other characteristics of SNPs-loaded Van.

Therefore, based on the above hypotheses and research questions, we synthesized and characterized SNPs with different pore sizes which were surface modified by different functional groups for the purpose of loading Van to improve its controlled release, permeability, and other characteristics. To achieve that, we designed and executed the work as follows: We

initiated our work by synthesizing and characterizing SNPs with different pore sizes. Here the SNPs were characterized for their particle size and morphology, surface area, charge, and porosity. We then functionalized the SNPs with different functional groups to achieve different cationic/anionic properties and polarity of SNPs surfaces. Then SNPs (functionalised or unfunctionalised) were loaded with Van and characterised. Finally, we performed the cytotoxicity assays for SNPs and carried out the permeability studies for SNPs-loaded Van using widely accepted Caco-2 cell monolayer assay.

## 2. Experimental


### 2.1. Chemicals

Vancomycin hydrochloride (#861987), hexadecyltrimethylammonium chloride (CTAC), triethanolamine (TEA), tetraethylorthosilicate (TEOS), 3-(trihydroxysilyl) propyl methyl-phosphonate (THMP), (3-aminopropyl) triethoxysilane (APTES), Dulbecco's modified Eagle medium (DMEM, D6546), Dulbecco's phosphate-buffered saline (PBS), fetal bovine serum (FBS, F9423) and MEM nonessential amino acid solution were purchased from Sigma-Aldrich (Australia). Dimethyl sulfoxide (DMSO), ammonium dihydrogen phosphate, and octadecyl trimethoxysilane (ODMS) were obtained from ThermoFisher Scientific (NJ, USA). Hank's

balanced salt solution (HBSS), pen-strep (penicillin  $10\,000\text{ U mL}^{-1}$  and streptomycin  $10\,000\text{ }\mu\text{g mL}^{-1}$ ), L-glutamine, sodium pyruvate ( $100\text{ mM}$ ), trypsin-EDTA, and (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Gibco (Thermo Fisher Scientific, Australia).

### 2.2. Synthesis of SNPs with different pore sizes

The synthesis of SNPs is described in Scheme 1A. The synthesis procedure for small pore-sized SNPs was slightly modified from the method reported by Chaudhary *et al.*<sup>55</sup> 2 g of CTAC and 0.04 g of TEA were dissolved in 20 mL of Milli-Q water and stirred (400 rpm) for 1 h at 95 °C. After 1 h, TEOS (1.5 mL) was added (dropwise) and the suspension mixture was, under the same conditions, stirred for another hour. The mixture was then cooled, and centrifuged ( $24\,650\times g$ , 15 min) to collect the particles as pellets. The particles were washed with ethanol (twice) and oven-dried at 60 °C overnight. Finally, they were crushed and calcined at 550 °C for 5 h. The resulting particles were designated as "SNPs SP". The synthesis procedure for large pore-sized SNPs was adapted from the method reported by Juère *et al.*<sup>56</sup> CTAC (8 mL) and TEA (360 mg) were dissolved in Milli-Q water (72 mL) and stirred (375 rpm) for 1 h at 60 °C. After 1 h, the pre-mixture of cyclohexane (32 mL) and TEOS (8 mL) was added, and the mixture was aged overnight under



**Scheme 1** Schematic illustration of (A) SNPs synthesis, (B) functionalisation with aminopropyl groups, (C) functionalisation with propyl methyl-phosphonate groups, and (D) functionalisation with octadecyl methyl groups.



similar conditions. The resulting product was centrifuged ( $24\,650\times g$ , 10 min) and the pellets were collected, washed twice with ethanol, oven-dried and then calcined. These particles were designated as “SNPs LP”.

### 2.3. Functionalisation of SNPs

SNPs functionalisation with aminopropyl groups (Scheme 1B) was done according to a previously reported method<sup>55</sup> with minor modifications. Prior to functionalisation, calcined SNPs (300 mg) were vacuum-dried (overnight) to remove off any possible excess moisture in the SNPs pores. The vacuum-dried SNPs (300 mg) were then added into toluene (45 mL), followed by bath sonication (5 min). To this dispersion, under stirring (400 rpm, at  $110\text{ }^{\circ}\text{C}$ ), 0.21 mL of APTES was added and the mixture was aged overnight under the same conditions. Functionalized SNPs (SNPs SP-NH<sub>2</sub> or SNPs LP-NH<sub>2</sub>) were then centrifuged ( $10\,950\times g$  for 10 min), washed with acetone two times and with ethanol once, then oven-dried overnight at  $60\text{ }^{\circ}\text{C}$ .

For functionalisation with propyl methyl-phosphonate groups<sup>55</sup> (Scheme 1C), THMP (0.13 mL) was dissolved in 13 mL of Milli-Q water, and the pH of the solution, which was highly basic (pH 12.0), was adjusted to slight acidic pH (pH 5–6) using concentrated hydrochloric acid solution (1 M). This lowering of pH is done to prevent hydroxylation and dissolution of silica during functionalisation. The above-prepared solution was added to SNPs suspension (100 mg of SNPs in 13 mL of Milli-Q water), then the mixture was stirred (400 rpm,  $100\text{ }^{\circ}\text{C}$ ) overnight. The functionalized SNPs were collected by centrifugation ( $10\,950\times g$  for 10 min), washed thrice with water and with ethanol twice, then oven-dried at  $60\text{ }^{\circ}\text{C}$ . The resulting functionalised particles were denoted “SNPs SP-PO<sub>3</sub> or SNPs LP-PO<sub>3</sub>”.

For hydrophobic (octadecyl methyl groups) functionalization (Scheme 1D), octadecyl methyl groups of ODMS were functionalised onto the SNPs surfaces. In this experiment, 200 mg of calcined SNPs were suspended in 30 mL of toluene containing 2% (v/v) of *n*-ODMS. After stirring (400 rpm) the mixture at  $110\text{ }^{\circ}\text{C}$  for 24 h, the particles were centrifuged ( $10\,950\times g$  for 10 min), washed three times with toluene and two times with ethanol, and then oven-dried at  $60\text{ }^{\circ}\text{C}$ . The particles after functionalisation with octadecyl methyl groups were designated “SNPs SP-CH<sub>3</sub> or SNPs LP-CH<sub>3</sub>”.<sup>43,57</sup>

### 2.4. Loading of Van in SNPs

Van was loaded in SNPs using a freeze-drying assisted method. In this method, Van loading in SNPs was done according to a previously reported procedure<sup>35,36</sup> with some modifications. 4 mL of aqueous-ethanolic solution containing 70 mg SNPs (SNPs SP or SNPs LP, with/without functional groups) was prepared as a suspension. 2 mL of Van aqueous solution ( $15\text{ mg mL}^{-1}$ ) was added to each SNPs suspension to make a mixture of 70:30% w/w (SNPs:Van, respectively). The suspension mixture was then stirred (300 rpm, at  $4\text{ }^{\circ}\text{C}$ ) overnight. Subsequently, the suspension mixture was frozen and then freeze-dried for 48 h using an Alpha Freeze Dryer (ALPHA 1–2 LD plus, Germany) and Van-loaded SNPs were obtained. The

loading capacity of Van in SNPs were determined using a thermo-gravimetric analysis (detailed in Section 2.5.6).

## 2.5. Characterisation of SNPs

**2.5.1. Particle size characteristics and surface charge.** The mean particle size, size distribution and surface charge of un-functionalised and functionalised SNPs were measured. 0.7 mg of SNPs was weighed, to which 3 mL of deionised water (DW) was added and vortexed for 2 min. Here DW containing 10% of ethanol was used for SNPs-CH<sub>3</sub>. The samples were then bath sonicated for 2 min and 2 mL of DW was added to the suspension, then vortexed and re-sonicated. The measurements were carried out with dynamic light scattering (DLS) with a Zeta-sizer Nano ZS (Malvern Instruments, Malvern) at room temperature with a scattering angle of  $173\text{ }^{\circ}\text{C}$ . Refractive indices of dispersion medium and dispersant were 1.330 and 1.420, respectively.

**2.5.2. Morphology of SNPs.** TEM images were obtained with a Hitachi 7700 microscope (TEM, USA) operating at 80 kV. SNPs (0.1 mg) were dispersed in 1 mL of ethanol, and bath sonicated (about 10 min). The suspension (a droplet) was then deposited onto a Cu grid (coated with carbon) and the ethanol was evaporated off before TEM imaging. For particle size determination from TEM images, ImageJ, a software for image processing and analysis, was used (the minimum number of particles analysed was 100). The shape and surface morphology of SNPs were analysed using a 7800-field emission SEM (FE-SEM, JEOL, USA) with a gentle beam. The samples (0.1 mg) were dispersed in ethanol (1 mL), vortexed and bath sonicated for approximately 10 min. The suspension (a droplet) was deposited onto silicon chip wafer (ProSciTech, Australia), fixed on carbon-impregnated double-sided adhesive tape (attached on a SEM specimen stub), and baked at  $50\text{ }^{\circ}\text{C}$  for 12 h using a vacuum oven. The samples were then plasma-cleaned using an Evactron<sup>®</sup> 25 plasma De-Contaminator (XEI Scientific, Inc., USA) prior to SEM imaging. The SEM images were taken at an acceleration voltage of 1 kV and the working distance of 3.8.

**2.5.3. Surface hydrophobic/hydrophilic properties of SNPs.** 5 mg of functionalised SNPs were dispersed in ethanol (1 mL) and stirred for 2 h at 500 rpm. Glass cover slips were washed with acetone and DW and dried. The ethanolic suspension of SNPs was drop-casted on the surface of glass cover slips and left to dry and after that the contact angle measurements were performed. The contact angle measurements were performed using the video-based fully automated contact angle measuring system (OCA 15EC, Dataphysics, Germany) equipped with high performance 6.5-fold zoom lens and electronic syringe unit and the measurements were done at ambient temperature ( $25\text{ }^{\circ}\text{C}$ ). Right and left angles between the tangent line and sample surface to the droplet were considered as one measurement. 5  $\mu\text{L}$  of DW (resistivity of  $18.25\text{ M}\Omega\text{ cm}$ ) was dispensed using motor driven syringe and the water contact angle was measured at regular time intervals to observe how SNPs surfaces behave over time, and a video was recorded (30 frames per second) for

every measurement. Un-functionalised SNPs were also measured with the same procedure.<sup>58</sup>

**2.5.4. Specific surface area and porosity of SNPs.** Nitrogen physisorption–desorption isotherms were measured (at  $-196\text{ }^{\circ}\text{C}$ ) using a Micromeritics Tristar II system (Tristar 3020, Micromeritics-II, Norcross, GA, USA), where nitrogen was the adsorbate and helium was used to calibrate the dead volume in the sample cell prior to the measurement. Before the analysis, SNPs were outgassed (at  $120\text{ }^{\circ}\text{C}$  for 12 h for un-functionalised SNPs and at  $100\text{ }^{\circ}\text{C}$  for 24 h for functionalized SNPs) to remove off any possible moisture in SNPs pores. The specific surface area was calculated using the Brunauer–Emmett–Teller (BET) equation from the adsorption data. Pore size distribution was determined by the Barrett–Joyner–Halenda (BJH) calculation using the desorption data.<sup>43</sup> The total pore volume was determined from the  $\text{N}_2$  amount adsorbed at relative pressure ( $P/P_0$ ) of 0.99.

**2.5.5. Particle surface chemistry and elemental analysis.** Surface elemental analysis of functionalised and un-functionalised SNPs was carried out using a Kratos Axis ULTRA X-ray Photoelectron Spectrometer (XPS) incorporated with a 165 mm hemispherical electron energy analyser. Monochromatic Al  $K\alpha$  X-rays ( $1486.6\text{ eV}$ ) at  $150\text{ W}$  ( $10\text{ mA}$ ,  $15\text{ kV}$ ) was used as the incident radiation. Wide (survey) scans were taken at an analyser pass energy of  $160\text{ eV}$ , over  $1200\text{--}0\text{ eV}$  binding energy range with  $1.0\text{ eV}$  steps and a dwell time of  $100\text{ ms}$ . Base pressure and analysis pressure in the analysis chamber were  $1.0 \times 10^{-9}$  torr and  $1.0 \times 10^{-8}$  torr, respectively. Samples were mounted on non-conductive substrate. Peak fitting and compositional analysis were done in CasaXPS version 2.3.14, using a linear baseline model, mixed Gaussian/Lorentzian 70:30-line shapes, and the Kratos Relative Sensitivity Factor (RSFs) library.

**2.5.6. Fourier transform-infrared (FTIR) and Thermogravimetric analysis (TGA).** FTIR analysis was done with Bruker Tensor FTIR spectrometer (Bruker Optik GmbH, Germany). The spectra were recorded between  $4000\text{ cm}^{-1}$  and  $350\text{ cm}^{-1}$  with data interval of  $0.5\text{ cm}^{-1}$  and resolution of  $4\text{ cm}^{-1}$  and the data were graphed as relative transmittance (%) vs. wave numbers ( $\text{cm}^{-1}$ ). TGA of the samples was done using Mettler Toledo DSC 2 STAR System and the sample weight was  $5\text{--}7\text{ mg}$ . The purge gas was nitrogen and heating was done under compressed air at the heating rate of  $10\text{ }^{\circ}\text{C min}^{-1}$ , over  $25\text{ }^{\circ}\text{C}$  to  $900\text{ }^{\circ}\text{C}$ . For every analysis, an empty crucible was used as a reference.

## 2.6. *In vitro* release studies

The method used for the release studies of Van-loaded SNPs was adapted from the method reported by Lopes *et al.*<sup>59</sup> with minor modifications, using SnakeSkin<sup>®</sup> Dialysis Tubing (Thermo Scientific, IL, USA). Van-loaded SNPs (equivalent to  $3\text{ mg}$  Van, based on TGA data) were dispersed in  $3\text{ mL}$  of donor medium and the resulting suspension was loaded into the dialysis tubing (molecular weight cut off  $10\text{ kDa}$ , tubing i.d of  $22\text{ mm}$ ) and knotted. The knotted dialysis tubing was placed in the reservoir containing the dialysate (PBS buffer pH 6.8, mimicking small intestinal pH) and the release was monitored

for 10 h. The systems were maintained at  $37\text{ }^{\circ}\text{C} \pm 1$  under moderate stirring ( $200\text{ rpm}$ ) throughout the whole experiment. At predetermined time intervals,  $0.5\text{ mL}$  of the release medium was taken for Van analysis, and it was replaced by the same volume of fresh medium pre-conditioned at  $37\text{ }^{\circ}\text{C}$ . The released Van amount was quantified by HPLC. The HPLC system and conditions used are described below.

## 2.7. High performance liquid chromatography method

In this study the HPLC method used for Van quantification was adapted from the methods reported earlier<sup>60,61</sup> with modifications. An HPLC system (Agilent Technologies) equipped with a diode array detector was used. The mobile phase consisted of  $88\%$  (v/v) of  $50\text{ mM}$  ammonium dihydrogen phosphate (adjusted to a pH of 4 using phosphoric acid) and  $12\%$  (v/v) of acetonitrile at a flow-rate of  $0.15\text{ mL min}^{-1}$ . Separation was carried out isocratically (at room temperature) on a GRACE Alltima HP C18  $3\text{ }\mu\text{m}$  column ( $150 \times 2.1\text{ mm}$ ) at  $220\text{ nm}$ . For Van analysis,  $10\text{ }\mu\text{L}$  of an aliquot withdrawn was injected, and the run time was  $12\text{ min}$ . Van eluted at about  $7\text{ min}$ . Van quantification was done from the standard calibration curve of Van with a linearity range of  $0.5$  to  $250\text{ }\mu\text{g mL}^{-1}$ . The calibration curve was linear (Fig. S2, ESI<sup>†</sup>). Both Pearson coefficient ( $r$ ) and correlation coefficient ( $r^2$ ) were  $0.9999$ .

## 2.8. *In vitro* cytotoxicity assays

Prior to permeability experiments, SNPs were investigated for their potential cytotoxicity to Caco-2 cell lines (Caco-2, ATCC HTB-37) using an MTT viability assay. Caco-2 cells (passage number: 40) were cultured in DMEM high glucose medium supplemented with  $10\%$  v/v of FBS and  $1\%$  v/v each of pen-strep, sodium pyruvate, MEM nonessential amino acids and L-glutamine and incubated at  $37\text{ }^{\circ}\text{C}$  in a humidity-controlled environment with  $5\%$   $\text{CO}_2$  in a cell culture incubator. After  $90\%$  confluence, the cells were trypsinized, harvested and then seeded into 96-well plates (cell density:  $10^5$  cells per well), then incubated for  $24\text{ h}$  under the same incubation conditions and subsequently treated with  $100\text{ }\mu\text{L}$  (per well) of suspensions of SNPs (concentrations ranging from  $25\text{--}500\text{ }\mu\text{g SNPs mL}^{-1}$  DMEM). This SNPs concentration range was chosen by considering the equivalent concentrations of SNPs used in transport experiments. Cells without treatment (DMEM only or DMEM +  $1\%$  DMSO) were used as controls. After a further  $24\text{ h}$  incubation, treatments were aspirated, and  $100\text{ }\mu\text{L}$  of MTT reagent ( $0.5\text{ mg mL}^{-1}$  in PBS) was added and then incubated at  $37\text{ }^{\circ}\text{C}$  for additional  $4\text{ h}$ . After that,  $100\text{ }\mu\text{L}$  DMSO per well was added to dissolve the crystals of formazan and the absorbance signal of formazan was measured at  $570\text{ nm}$  using a microplate reader (SPECTROstar Nano, BMG LABTECH).

## 2.9. Permeability experiments

**2.9.1. Caco-2 cell culturing.** Caco-2 cells (Caco-2, ATCC HTB-37) were cultured and grown in DMEM high glucose medium supplemented with  $10\%$  v/v of FBS and  $1\%$  v/v each of pen-strep, sodium pyruvate, MEM nonessential amino acids and L-glutamine and incubated in cell culture incubator at

37 °C in a humidity-controlled atmosphere with 5% CO<sub>2</sub>. After reaching 90% confluence, cells were trypsinized, harvested, and cell seeding followed. Here trypsinization involved aspirating the media, followed by washing with 10 mL of PBS, and cell detachment by addition of 2 mL of trypsin–EDTA. The cells were then incubated for 2 min and 8 mL DMEM was added to neutralise trypsin–EDTA. The cell suspension was then centrifuged (200×*g*, 2 min) and supernatant was aspirated. The resulting cell pellets were then re-suspended in 2 mL of fresh DMEM, followed by cell seeding.

**2.9.2. Formation of Caco-2 cells monolayer.** The Caco-2 cells (Caco-2, ATCC HTB-37) used for seeding were of between passage number 35 and 38 and each experiment was performed in triplicate using 12 *trans*-well inserts (0.4 μm pore diameter, 1.12 cm<sup>2</sup> area) (Corning Inc., Kennebunk, ME, USA) plates. After re-suspending the cell pellets in fresh DMEM (as described above), the cells were counted using a cell counter (TC20™ Automated Cell Counter, Bio-Rad Laboratories, Inc.) and the cells (~97% viable cells) count was adjusted to 2 × 10<sup>5</sup> mL<sup>-1</sup> using fresh DMEM medium. Then, a 0.5 mL cell suspension was seeded into the apical chamber of 12 *trans*-well inserts whereas 1.5 mL of fresh DMEM was added into the basolateral chamber. The plates were then incubated at 37 °C with 5% CO<sub>2</sub> in humidified atmosphere and the media was changed every 2 days, by decanting and aspirating the media from apical chamber and basolateral chamber, respectively, and replacing with an equal volume of fresh DMEM (pre-conditioned at 37 °C). Van transport experiments were done between 17 to 21 days after seeding. The Trans-epithelial electrical resistance (TEER) across the Caco-2 cells monolayers was recorded using Millicell<sup>®</sup> ERS-2 Epithelial Volt–Ohm Meter to assess the monolayer formation and integrity. The TEER values were calculated using the equation below and the monolayers were considered appropriate for the experiment when their TEER values were > 600 Ω cm<sup>2</sup>.<sup>62,63</sup>

$$\text{TEER } (\Omega \text{ cm}^2) = [\text{TEER } (\Omega) - \text{TEER}_{\text{background}} (\Omega)] \times A \text{ (cm}^2\text{)} \quad (1)$$

TEER (Ω) is the electrical resistance across Caco-2 cell monolayers, TEER<sub>background</sub> (Ω) is the resistance across the cell-free inserts, and A (cm<sup>2</sup>) is the surface area of the inserts, 1.12 cm<sup>2</sup>.

**2.9.3. Van transport (Apical to Basolateral) experiments.** Prior to transport experiments, each monolayer was washed and equilibrated with the transport medium (HBSS) for 20 min (at 37 °C with 5% CO<sub>2</sub> in humidified atmosphere) and the TEER values were recorded after equilibration. After that, the medium from apical compartments was decanted and the inserts were transferred into new 12-well clusters containing 1.5 mL of basolateral HBSS. Then 0.5 mL of treatment solution (concentration of 200 μg Van mL<sup>-1</sup> HBSS for pure Van (un-encapsulated) or an equivalent concentration of Van-loaded SNPs) was added to the apical compartment and the initial TEER values (TEER<sub>0</sub>) were measured. Here it is noteworthy to mention that Van-loaded SNPs-CH<sub>3</sub> were suspended in HBSS containing 1% DMSO instead of pure HBSS. This was done to ensure that Van-loaded SNPs-CH<sub>3</sub> did not precipitate after

suspension in HBSS due to the hydrophobic nature of SNPs-CH<sub>3</sub>. Blank HBSS and HBSS + 1% DMSO were used as controls. Van-free SNPs (un-loaded SNPs, functionalised or non-functionalised) were also investigated under the same conditions. The concentration of SNPs in HBSS was equivalent to the ones used in Van-loaded SNPs. This was done in order to investigate the change of TEER values of Caco-2 cell monolayers when treated with un-loaded SNPs. The plates were then placed in a shaking incubator (John Morris Scientific, Australia, at 37 °C and 100 rpm) to minimize the impact of the unstirred water layer.<sup>64</sup> At appropriate time points, sample (500 μL) from the basolateral compartment was taken and Van was analysed by HPLC (described above). The volume of basolateral compartment was maintained (to maintain sink conditions) by replacing the withdrawn volume by the equal volume of pre-conditioned HBSS. The apparent permeability coefficient (*P*<sub>app</sub>, cm s<sup>-1</sup>) was determined according to the following equation:

$$P_{\text{app}} = \left( \frac{dQ}{dt} \right) \left( \frac{1}{A \cdot C_0} \right) \quad (2)$$

where *dQ/dt* is the flux of Van across the Caco-2 cell monolayer (μmol s<sup>-1</sup>), *C*<sub>0</sub> is the initial concentration of Van in the apical compartment (μM), and *A* is the surface area of the Caco-2 cell monolayer (1.12 cm<sup>2</sup>).

## 2.10. Data processing and statistical analysis

Descriptive statistics and analysis of variance were carried out with GraphPad Prism 9.0.0 and the results are presented as mean values ± SDs (*n* = 3, unless otherwise specified). One-way ANOVA (assuming Gaussian distribution of residuals) with Tukey's multiple comparisons test was carried out and the significant difference was considered when the *P* value was < 0.05. Where other specific statistical tests were performed, they are given in the table or figure legends.

## 3. Results and discussion

### 3.1. Particle size and morphology of SNPs

Particle size and morphology are key attributes when designing nanomaterials for drug delivery systems. Specifically for oral delivery, size and morphology of nanoparticles matter since the particles have to be of particular size and morphology to permeate the intestinal mucus layer and cross the intestinal epithelium.<sup>30</sup> Specific size and morphology of SNPs can be accomplished by fine-tuning the amount of CTAC (an organic chloride salt of cetyltrimethylammonium, a cationic surfactant used during synthesis for micelle formation to make a template), TEA (a tertiary amine and a triol, used as a base catalyst to catalyse the hydrolysis and condensation reactions of silicate species),<sup>65</sup> and TEOS (an ethyl ester of orthosilicic acid, which is used as a precursor to silica template in SNPs synthesis). TEA also plays an important role as surface capping agent to stabilize the particles against aggregation and thus producing monodispersed system.<sup>66,67</sup> Other process conditions, including temperature at which the process is carried out and time of

Table 1 Particle size characteristics of SNPs

SNPs	Count rate <sup>a</sup> (kcps)	Mean particle size (nm) ± SD		Polydispersity index (PDI) ± SD <sup>d</sup>
		DLS <sup>b</sup>	TEM <sup>c</sup>	
SNPs SP	266	128 ± 41 <sup>#</sup>	100 ± 7	0.26 ± 0.02 <sup>#</sup>
SNPs SP-NH <sub>2</sub>	270	232 ± 81*	110 ± 24	0.37 ± 0.07*
SNPs SP-PO <sub>3</sub>	360	292 ± 99**	105 ± 10	0.42 ± 0.09**
SNPs SP-CH <sub>3</sub>	290	779 ± 125***	116 ± 54	0.89 ± 0.2****
SNP LP	324	152 ± 46 <sup>#</sup>	130 ± 12	0.32 ± 0.06 <sup>#</sup>
SNPs LP-NH <sub>2</sub>	330	212 ± 87 <sup>ns</sup>	132 ± 15	0.39 ± 0.04 <sup>ns</sup>
SNPs LP-PO <sub>3</sub>	380	158 ± 60 <sup>ns</sup>	130 ± 16	0.34 ± 0.04 <sup>ns</sup>
SNPs LP-CH <sub>3</sub>	286	329 ± 51**	140 ± 18	0.42 ± 0.08*

<sup>a</sup> Count rates are for DLS measurements. <sup>b</sup> Particle size were measured by DLS. The means are average of the means of three measurements. SDs are average of the SDs of three measurements. <sup>c</sup> Mean particle size measured by SEM (count number: 100). The numbers are not the average of three measurements. Here the SDs are indicative of size distribution. <sup>d</sup> PDIs are from DLS measurements. The numbers are average of PDIs of three measurements. <sup>#</sup> Indicates that there was no significant difference in particle size between SNPs SP and SNPs LP. \*Functionalised SNPs showed the significant difference in comparison to their un-functionalised SNPs. <sup>ns</sup> Functionalised SNPs showed no significant difference in comparison to their un-functionalised SNPs. One-way ANOVA with Tukey's multiple comparisons test was performed. ns: no significance; significance level was \* $p < 0.033$ , \*\* $p < 0.002$ , \*\*\* $p < 0.0002$ , \*\*\*\* $p < 0.0001$ .

the process, play a major role in the size of the produced SNPs.<sup>68</sup> After the preparation and surface functionalisation of SNPs, the SNPs were firstly characterized for their size characteristics by DLS, and the results are shown in Table 1 and Fig. S3 (ESI<sup>†</sup>). In general, un-functionalised SNPs SP showed slightly lower mean particle size and narrow distribution compared to un-functionalised SNPs LP. As shown in Table 1, the mean particle sizes were 128 ± 41 and 152 ± 46, respectively for SNPs SP and SNPs LP and their respective PDIs were 0.26 ± 0.02 and 0.32 ± 0.06, which underscores the effect of process conditions on the rate of precursor conversion, nucleation, and growth of SNPs (which affect the particle size characteristics). The results in Table 1 also illustrate the impact that the molar ratio variation of precursors had on particle size characteristics of synthesised SNPs.<sup>69,70</sup> Specifically, to the amount of precursor (TEOS), the more TEOS is added, the more the particles could grow and *vice versa*,<sup>69,70</sup> which concur with our experiments since the amount of TEOS used for the SNPs SP synthesis was 1.5 mL, with an increase to 8 mL for SNPs LP.

Particle size characteristics of functionalised SNPs are shown in Table 1. In general, compared to un-functionalised SNPs, functionalised SNPs showed higher hydrodynamic diameters and broader particle size distribution in aqueous medium when measured by DLS. For example, when SNPs SP was functionalised with -NH<sub>2</sub> and -PO<sub>3</sub>, the particle size and PDI values increased significantly to 232 ± 81 and 292 ± 99 and 0.47 ± 0.07 and 0.52 ± 0.09, respectively, which was almost a two-fold increase compared to un-functionalised ones.

Similarly, -NH<sub>2</sub> and -PO<sub>3</sub> functionalised SNPs LP showed an increase in mean particle size and PDI compared to un-functionalised SNPs LP although it was not at the same magnitude as SNPs SP. This suggests that in aqueous medium the modified SNPs might have aggregated to some extent, due to the presence of functional groups which might have decreased the electrical double layer thickness under the condition of high ionic strength, even if their surface charges were higher compared to pure SNPs.<sup>57</sup> Moreover, specifically to -NH<sub>2</sub> functionalised SNPs, this might have originated from the electrostatic attraction between cationic amino groups and free (un-functionalised) silanol groups remaining at the surfaces of SNPs-NH<sub>2</sub>.<sup>71</sup> Surface functionalisation with octadecyl methyl groups even further increased the mean particle size and PDI values. The mean particle size increased to 779 ± 125 for SNPs SP-CH<sub>3</sub> and 329 ± 51 for SNPs LP-CH<sub>3</sub> with similar increase in PDI (0.89 ± 0.2 and 0.42 ± 0.08, respectively). This large increase suggests that that severe aggregation among SNPs-CH<sub>3</sub> might have occurred due to the hydrophobic nature of octadecyl chains of ODMS which might have hindered the solubilisation and promoted the aggregation even if 10% of ethanol was used in suspension for SNPs-CH<sub>3</sub> in DLS. Here the SNPs functionalized with octadecyl methyl groups have a smaller shear or slippage plane, and the octadecyl groups extending from SNPs-CH<sub>3</sub> surfaces are outside the shear plane, which leads to strong hydrophobic interactions between neighbouring particles, and this might lead to aggregation.<sup>72,73</sup>

TEM images were analysed for mean particle size using ImageJ and results are presented in Table 1. The mean particle sizes and the standard deviations for TEM mean particle sizes were lower than DLS. For instance, the TEM mean particle size for SNPs SP and SNPs LP were 100 ± 7 and 130 ± 12 down from 128 ± 41 and 152 ± 46 (DLS). Also, TEM mean particle sizes of functionalised SNPs were lower compared to DLS. This significant difference between TEM and DLS data in terms of mean particle size values might be explained by understanding the working principles of these two techniques. In TEM particles are directly observed under the microscope, while the DLS technique indirectly measures size using the principle of dynamic light scattering based on Brownian motion to detect diffusion coefficient of particles.<sup>74</sup> Formation of a hydration layer around the particles (since particles are dispersed in DW in the case of DLS technique) will lead to larger apparent particle sizes (hydrodynamic diameters) compared to TEM.

The particle morphology and pore structures of all SNPs samples were assessed by TEM and SEM analysis. TEM and SEM images are displayed in Fig. 1 and Fig. S4, S5 (ESI<sup>†</sup>). The TEM images show particles with well-defined spherical shape, although SNPs SP-CH<sub>3</sub> were somewhat aggregated (Fig. S4C, ESI<sup>†</sup>) compared to other functionalised SNPs, which concurs with their comparatively high mean particles size and PDI values. These SNPs were spherical with slightly rough outer surfaces (Fig. S6, ESI<sup>†</sup>) and they showed a highly ordered network of mesopores. Moreover, from TEM and SEM images (Fig. 1), there is clear difference in the pore structures between SNPs SP and SNPs LP. The highly ordered network of pores in






Fig. 1 Morphology of SNPs imaged by TEM (A) SNPs SP & (B) SNPs LP and SEM (C) SNPs SP & (D) SNPs LP.

SNPs SP are present as an array of small pores that are still readily observed from the images (Fig. 1 and Fig. S6, ESI<sup>†</sup>). In comparison, the large pores of the SNPs LP exhibit flower-like (or worm-like) structures (Fig. 1 and Fig. S6, ESI<sup>†</sup>). Furthermore, in the case of SNPs LP, two populations of pores can be differentiated: smaller pores in the centre and larger ones at the rim (Fig. S6, ESI<sup>†</sup>).<sup>66,75</sup> After functionalization of the SNPs, TEM and SEM images showed that the original structure of the particles and pores were still preserved (Fig. S4 and S5, ESI<sup>†</sup>), although the surface of SNPs-CH<sub>3</sub> was slightly smoother, most likely due to the longer octadecyl chains on the SNPs surfaces after -CH<sub>3</sub> functionalisation.

### 3.2. Surface area and porosity of SNPs

The specific surface area, pore volume and size, and pore size distribution of nanoparticles are important factors for drug encapsulation and/or adsorption and other characteristics of loaded drugs.<sup>76</sup> They play important role in drug loading capacity, drug dissolution, kinetics of drug release and other characteristics.<sup>77</sup> Although EM techniques give us information about the morphology and pore structures of SNPs, they still are qualitative techniques. Therefore, it was important to investigate the surface characteristics and porosity of SNPs with other techniques which are more quantitative. The nitrogen physisorption analysis is one technique which provides more detailed and quantitative analyses for surface area properties and porosity of SNPs. The technique is based on Brunauer–Emmett–Teller (BET) theory (an extension of the Langmuir theory, which is a theory of monolayer molecular adsorption), where it applies to systems of multilayer molecular adsorption and uses probing gases to quantify specific surface area and porosity of particles. Therefore, nitrogen adsorption/desorption experiments were used here to investigate the surface area and porosity nature of SNPs (functionalised and un-functionalised) and the results are shown in Fig. S7, S8 (ESI<sup>†</sup>) and Table 2.

The nitrogen adsorption/desorption isotherms for un-functionalised and functionalised SNPs are shown in Fig. S7 (ESI<sup>†</sup>).

Table 2 Surface area and porosity of functionalised and un-functionalised SNPs

SNPs	BET surface area [m <sup>2</sup> g <sup>-1</sup> ]	Pore volume [cm <sup>3</sup> g <sup>-1</sup> ]	Pore size [nm]
SNPs SP	411.50	0.583	2
SNPs SP-NH <sub>2</sub>	300.9	0.207	2
SNPs SP-PO <sub>3</sub>	365.2	0.379	2
SNPs SP-CH <sub>3</sub>	269.97	0.180	2
SNPs LP	623.87	1.343	9.2
SNPs LP-NH <sub>2</sub>	395.82	0.760	8.2
SNPs LP-PO <sub>3</sub>	457.18	0.938	9.2
SNPs LP-CH <sub>3</sub>	486.07	0.989	8.2

Fig. S7A (ESI<sup>†</sup>) shows the nitrogen adsorption/desorption isotherms for SNPs SP. It shows a type IV isotherm characteristic of pores of silica nanoparticles, indicating a mesoporous structure. The figure shows that the isotherm is composed of different regions depend on the adsorption process. Here at very low pressures, the pores are filled with adsorbate (nitrogen gas). At the knee (around  $P/P_0 = 0.05$ ), monolayer formation begins. The plateau region in the middle shows the formation of a monolayer, followed by multi-layer formation at medium pressures. At higher pressures, capillary condensation occurs. Here the adsorption/desorption patterns exhibited a major capillary condensation at a high relative pressure ( $P/P_0$ ) of around 0.9. Moreover, SNPs SP N<sub>2</sub> sorption isotherms showed Type H1 hysteresis loops, which is characteristic of silica materials with narrow range of mesopores, as for example in templated silicas.<sup>78</sup> Fig. S7B (ESI<sup>†</sup>) shows the nitrogen adsorption/desorption isotherms for SNPs LP. It was found that all SNPs LP exhibited type IV isotherms.<sup>78</sup> Similar to SNPs SP, SNPs LP isotherms show that the adsorption process occurred *via* multilayer adsorption followed by capillary condensation.<sup>78</sup> As can be seen on the Fig. S7B (ESI<sup>†</sup>), there is a slight increase in the initial part of the isotherm which shows the stage where the monolayer formation is completed, which is followed by multilayer formation, although the pattern and hysteresis of isotherms are slightly different from SNPs SP. Here, at low relative pressure range, the gas (N<sub>2</sub> in this case) adsorbs and condense in the tiny capillary pores of the SNPs at pressures below the saturation pressure of the gas, due to the presence of smaller pores of about 2–4 nm, as can be seen in the profile of pore size distribution of SNPs LP (Fig. S8B and S6, ESI<sup>†</sup>). However, since SNPs LP has also large pores (Fig. S7B and S6, ESI<sup>†</sup>), after the initial region, there is a gradual increase of adsorption process observed at relative pressure range ( $P/P_0$ ) of 0.8–0.85, followed by the pore condensation step happening at higher relative pressure range, with a sharp hysteresis loop, characteristic of capillary condensation of the nitrogen occurring inside the mesopores, still with type IV isotherm nature.<sup>75</sup> Moreover, SNPs LP N<sub>2</sub> sorption isotherms showed Type H5 hysteresis loops, which is a distinctive form associated with certain pore structures containing mesopores with wider openings.<sup>78</sup> Functionalising SNPs (both SNPs SP and SNPs LP) did not change the shape and type of the N<sub>2</sub> adsorption/desorption isotherms although the adsorption plateau values and the quantity (cm<sup>3</sup> g<sup>-1</sup>) of N<sub>2</sub> adsorbed decreased, reflecting the decrease of total surface area of functionalised SNPs in comparison to un-functionalised ones.

Table 2 shows BET surface areas and porosity of functionalised and un-functionalised SNPs. SNPs SP showed BET surface area of  $411.50 \text{ m}^2 \text{ g}^{-1}$  while SNPs LP exhibited BET surface area of  $623.87 \text{ m}^2 \text{ g}^{-1}$ , probably due to the difference in the amount of precursors and surfactants and process conditions used in synthesis of these two SNPs.<sup>79</sup> BET surface area values decreased remarkably when SNPs surfaces were modified with different functional groups. For example, the BET surface area of SNPs SP was remarkably decreased to 300.9, 365.2, 269.97  $\text{m}^2 \text{ g}^{-1}$  when SNPs SP was functionalised with  $-\text{NH}_2$ ,  $-\text{PO}_3$ , and  $-\text{CH}_3$ , respectively. Similarly, the functionalisation of SNPs LP induced a remarkable reduction of BET surface area to 395.82, 457.18, 486.07  $\text{m}^2 \text{ g}^{-1}$ , when functionalised with  $-\text{NH}_2$ ,  $-\text{PO}_3$ , and  $-\text{CH}_3$ , probably due to the presence of additional grafted groups on the internal and external pore surfaces of SNPs, which reduced surface areas.<sup>66</sup> In addition, it is noteworthy to mention that different functional groups produced different reduction levels of BET surface areas. For instance, with SNPs SP, while  $-\text{NH}_2$  functionalised SNPs SP showed a 27% reduction in BET surface area compared to un-functionalised SNPs SP,  $-\text{PO}_3$  functionalised SNPs SP showed only a 11% reduction, while  $-\text{CH}_3$  functionalised SNPs SP showed a 34% reduction. This might be due to a different number of functional groups and the chemical structure of the anchored groups as octadecyl methyl chains are longer than the short propyl chains of APTES and THMP (Scheme 1D vs. B and C).

The size distribution of pores is another important characteristic of porous nanomaterials. Pore size distribution curves

were determined from the adsorption branch by the BJH method, and the results are shown in Fig. S8 (ESI<sup>†</sup>) and summarised in Table 2. SNPs SP showed narrow-distributed pores with a high population at 2 nm whereas SNPs LP were widely distributed with majority of pores in the range of 4–18 nm and a peak population at 9 nm. TEM and SEM images corroborate these above results as it can be seen in Fig. 1, where SNPs SP and SNPs LP show distinctive pores size variations roughly matching the BJH results. As shown in Table 2, SNPs LP, irrespective of whether functionalised or not, have relatively higher pore volumes ranging from 1.343 to 0.989  $\text{cm}^3 \text{ g}^{-1}$  compared to SNPs SP (0.583–0.180  $\text{cm}^3 \text{ g}^{-1}$ ). Functionalisation affected pore volume, decreasing from 0.583 to 0.207, 0.379, and 0.180  $\text{cm}^3 \text{ g}^{-1}$  when SNPs SP were functionalised with  $-\text{NH}_2$ ,  $-\text{PO}_3$ , and  $-\text{CH}_3$ , respectively and from 1.343 to 0.760, 0.938, and 0.989  $\text{cm}^3 \text{ g}^{-1}$  when SNPs LP were functionalised with  $-\text{NH}_2$ ,  $-\text{PO}_3$ , and  $-\text{CH}_3$ , respectively. The pore size of functionalised SNPs-SP did not change whereas pore size of functionalised SNPs LP were only slightly reduced to 8.2 nm (from 9.2 nm) in the case of  $-\text{NH}_2$  and  $-\text{CH}_3$  functionalised SNPs LP. In general though, regarding functionalisation of SNPs, as it can be seen in TEM and SEM images, neither the change of pore size distribution nor the reduction of BET surface areas have greatly affected the morphology of either SNPs SP or SNPs LP.

### 3.3. Anionic and cationic properties of SNPs

**3.3.1. Surface charge of SNPs by DLS.** Besides particle size and morphology, the surface polarity and surface charge of



Fig. 2 Surface charge of SNPs with/without functional groups. Values are presented as mean  $\pm$  standard deviation ( $n = 3$ ). One-way ANOVA with Tukey's multiple comparisons test was performed. ns: no significance; significance level was \* $p < 0.033$ , \*\*\*\* $p < 0.0001$ .

SNPs play a key role in cellular uptake or trans-epithelial delivery of drugs.<sup>48</sup> Therefore, our aim here was to investigate whether functionalisation changed the surface charge of SNPs, which would alter the SNPs surface characteristics and possibly change how SNPs can interact with epithelial cells. Surface charge measurements were performed by DLS and the results in terms of zeta potential are displayed in Fig. 2. For un-functionalised SNPs both SNPs SP and SNPs LP showed a negative surface charge with zeta potential values of  $-26.33 \pm 0.58$  mV and  $-23.03 \pm 2.58$  mV respectively (no significant difference), as expected due to negatively charged silanol groups on their surface.<sup>80</sup> Functionalisation (for both SNPs SP and SNPs LP) significantly altered their surface charge values. Unsurprisingly, addition of aminopropyl groups (APTES) gave a cationic property to SNPs surfaces whereas propyl methyl-phosphonate (THMP) and octadecyl methyl groups (ODMS) either increased or decreased the anionic level of SNPs surfaces. When functionalised with aminopropyl group (SNPs-NH<sub>2</sub>), the surface charges of SNPs SP and SNPs LP were significantly ( $p < 0.05$ ) changed to positive with zeta potentials of  $+32.67 \pm 0.55$  and  $+22.97 \pm 0.60$  for SNPs SP-NH<sub>2</sub> and SNPs LP-NH<sub>2</sub>, respectively, demonstrating the successful amino-silanisation of SNPs surfaces.<sup>81</sup> Functionalisation of SNPs with propyl methyl-phosphonate (SNPs-PO<sub>3</sub>) led to more highly negative zeta potential values, with SNPs SP surface charge significantly ( $p < 0.05$ ) increasing from  $-26.33 \pm 0.58$  mV to  $-34.1 \pm 0.52$  mV and SNPs LP surface charge increasing from  $-23.03 \pm 2.58$  mV to  $-26.27 \pm 1.41$  mV. This confirms successful grafting of anionic propyl methyl-phosphonate groups on SNPs surfaces, which added additional negative charges and consequently increased their negative zeta potentials.<sup>80</sup> Finally, functionalisation with octadecyl methyl groups significantly ( $p < 0.05$ ) reduced the negative surface charge of SNPs, but unlike SNPs-NH<sub>2</sub> the zeta potentials did not shift to positive. The zeta potentials were reduced to  $-17.83 \pm 0.23$  mV and  $-13.57 \pm 1.55$  mV, respectively, when SNPs SP and SNPs LP were functionalised with octadecyl methyl groups, consistent with addition of the octadecyl methyl groups masking the negatively charged silanols. The type of pores did appear to have an impact on the surface charge: although un-functionalised SNPs SP and SNPs LP did not differ significantly ( $p > 0.05$ ) in their zeta potentials, for all functional groups, functionalised SNPs SP showed significantly higher zeta potentials than functionalised SNPs LP.

**3.3.2. Fourier transform-infrared (FTIR).** To study more the molecular structures of synthesized SNPs, FTIR measurements were performed. First, we did FTIR of un-calcined SNPs to see whether calcination was successful. Fig. S9 (ESI<sup>†</sup>) shows that the non-calcined SNPs had obvious characteristic peaks of surfactant at 2856 and 2926 cm<sup>-1</sup> (stretching vibration peaks of -CH<sub>2</sub>, due to presence of CTAC and TEA) and had a shear vibration peak of 1478 cm<sup>-1</sup> of a tertiary amine. Following template removal by calcination, the -CH<sub>2</sub> characteristic peaks disappeared, which confirmed an effective calcination process to remove organic species. Fig. S10 (ESI<sup>†</sup>) shows the FTIR spectra of un-functionalised (calcined) and functionalised SNPs

in the range of 360–4000 cm<sup>-1</sup>. Un-functionalised SNPs exhibited IR peaks at the bands attributed to siloxane Si–O–Si bending vibration (451 cm<sup>-1</sup>), symmetric stretching of Si–O–Si (798 cm<sup>-1</sup>), Si–O–Si asymmetric stretching (1072 cm<sup>-1</sup>) and a broad -OH stretching band (3032–3692 cm<sup>-1</sup>) of outer surface silanol groups (Si–OH). An -OH bending vibration that likely originated from physisorbed water molecules in SNPs (corroborated by TGA) appeared at 1639 cm<sup>-1</sup>.

The FTIR spectra of functionalised SNPs are presented in Fig. S10 (ESI<sup>†</sup>) and chemical changes in surface structures consistent with the new chemical groups can be clearly seen. After functionalization with -NH<sub>2</sub>, the SNPs maintained its structure with no major changes in the Si–O–Si framework. However, the existence of aminopropyl functional groups was confirmed by the appearance of peaks at 2966 cm<sup>-1</sup> and 2901 cm<sup>-1</sup>, which were stretching vibration peaks of methylene groups (-CH<sub>2</sub>-). Furthermore, a new absorption peaks appeared at 1491 cm<sup>-1</sup> and 1409 cm<sup>-1</sup> which correspond to the N–H stretching vibrations of the primary and secondary amines of APTES.<sup>66</sup> For -PO<sub>3</sub> functionalised SNPs, the existence of the propyl methyl-phosphonate groups was confirmed by the presence of the symmetric and asymmetric stretching vibration bands at 2966 cm<sup>-1</sup> and 2901 cm<sup>-1</sup> (methylene), which shows the presence of propyl groups from THMP. Also, weak additional peaks are observable at 1406 and 1392 cm<sup>-1</sup> which might correspond to phosphonate P–O groups. The FTIR spectra also confirmed the grafting of octadecyl methyl groups to the SNPs due to the presence of characteristic vibration bands of the octadecyl methyl groups of ODMS. The band at 2897 cm<sup>-1</sup> (symmetric C–H vibrations) accompanied by an intensive band at 2922 cm<sup>-1</sup> (asymmetric C–H vibration of methyl group) in the spectra of SNPs-CH<sub>3</sub> indicate a high concentration of grafted octadecyl methyl groups (alkyl chain of silane molecules on the SNPs surfaces) which also correlate with the data of elemental composition (discussed in detail in Section 3.4) and TGA showing high yield of octadecyl methyl groups grafted on the SNPs surfaces.<sup>72</sup> Another important observation in all the functionalised SNPs was that the intensity of the peak 3440 cm<sup>-1</sup>, the broad peak corresponding to Si–OH groups, was reduced or in some cases disappeared from the spectra of modified SNPs, due to the silanol groups being modified by the functional groups.<sup>82</sup> Moreover, we can see that the water physisorption band at 1620 cm<sup>-1</sup> is seen in all functionalised SNPs, indicating the hygroscopic nature of SNPs,<sup>83</sup> although this peak intensity slightly diminishes for SNPs functionalised by the hydrophobic octadecyl methyl groups.

**3.3.3. Thermogravimetric analysis (TGA).** The degree of functionalisation in each SNPs was determined by TGA and the results are given in Fig. S11 (ESI<sup>†</sup>). For un-functionalised SNPs, an initial slight weight loss ( $\approx 3\%$ ) was observed, which is likely due to the desorption of physisorbed water molecules.<sup>83</sup> For functionalised SNPs, there was an initial slight weight loss (similar to un-functionalised SNPs, likely due to the physisorbed water), followed by a significant weight loss occurring up to 700 °C, which was ascribed to different steps of the thermal degradation of the functional groups (with their alkyl

chains) grafted on the SNPs surfaces.<sup>84</sup> Also, SNPs with different functional groups exhibited differences in their decomposition patterns, indicating the difference in nature of their decomposable organosilane species. It can also be seen that the thermal decomposition of the organic functional groups attached on the SNPs surfaces occurred in the interval of temperature between 150 and 650 °C. When functionalised, the weight loss at 800 °C was around 8%, 9%, and 17% for SNPs SP-NH<sub>2</sub>, SNPs SP-PO<sub>3</sub>, and SNPs SP-CH<sub>3</sub>, respectively whereas SNPs LP-NH<sub>2</sub>, SNPs LP-PO<sub>3</sub>, and SNPs LP-CH<sub>3</sub> showed the weight loss of 9.8%, 9.6%, and 9.1%, respectively, which shows the decomposition of amine, phosphonate and octadecyl groups.


### 3.4. Hydrophilicity and hydrophobicity of SNPs

**3.4.1. Contact angle measurements.** Contact angle measurements were performed both on un-functionalised and functionalised SNPs in order to investigate whether the functionalisation with octadecyl methyl silanes lead to increased SNPs surface hydrophobicity, which with our hypothesis would contribute to the permeation behaviours of Van. The initial contact angles of un-functionalised SNPs and SNPs functionalised with polar cationic aminopropyl groups (SNPs-NH<sub>2</sub>) and polar anionic propyl methyl-phosphonate groups (SNPs-PO<sub>3</sub>) were low (Fig. 3). When the water droplet was placed on the un-functionalised SNPs, there was a complete spreading and absorption of the droplet on the SNPs surface, which indicates the hydrophilic nature of un-functionalised SNPs (Fig. 3 and Fig. S12, S13, ESI†). The initial contact angles (contact angle at time 0) of un-functionalised SNPs for SNPs SP and SNPs LP were 30.5° and 33°, respectively, which shows the hydrophilic nature of silanols on SNPs surfaces (as already discussed above). When SNPs were functionalised with aminopropyl groups (SNPs-NH<sub>2</sub>) and propyl methyl-phosphonate groups (SNPs-PO<sub>3</sub>), although minor variations in contact angle values compared to un-functionalised SNPs were observed, SNPs maintained their hydrophilicity, with contact angle values ranging between 29–22°. Contrary to un-functionalised SNPs and functionalised SNPs (SNPs-NH<sub>2</sub> and SNPs-PO<sub>3</sub>), functionalisation with octadecyl methyl group (SNPs-CH<sub>3</sub>) significantly

increased the contact angle values (Fig. 3) from 30.5° and 33° for un-functionalised SNPs SP and SNPs LP, respectively, to 91° and 94°, indicating the increased hydrophobicity of SNPs-CH<sub>3</sub>, which might have been due to the replacement of hydrophilic sites (silanols) on SNPs surfaces with hydrophobic octadecyl methyl groups, which reduced the surface energy and increased the water droplet surface tension which consequently increased the contact angle values.

When the droplet (water droplet in this case) is sufficiently small, surface tensions dominate over gravity and the forces that acts on the droplet set the contact angle. If the droplet volume and surface tension of the system do not change, the contact angle remains constant.<sup>85</sup> But, as time goes, the change in the volume of the droplet, shape, and surface tension may occur<sup>86</sup> and different SNPs with different surfaces in their nature (in this case SNPs vs. -CH<sub>3</sub> modified SNPs) may behave differently over time, and consequently a new equilibrium of forces which act on a droplet might produce a different contact angle. Therefore, the variation of contact angles over time were investigated. For un-functionalised SNPs, initially the contact angle slightly decreased then becomes almost constant for over 4 minutes. For SNPs functionalised with -NH<sub>2</sub> and -PO<sub>3</sub>, there is a more noticeable change of contact angle values over time. The behaviour of SNPs functionalised with -CH<sub>3</sub> differed between the two types of particles. While the contact angle of SNPs SP-CH<sub>3</sub> was almost unchanged over 4 minutes, there was an initial slight decrease (from 94° to 90°) followed by a very small gradual change of contact angle values for SNPs LP-CH<sub>3</sub>, although their contact angle values were still high. This might have been due to the difference in the number of octadecyl methyl groups on surfaces of -CH<sub>3</sub> functionalised SNPs, or the larger pore size of the SNPs LP.

When the surface modified SNPs are loaded with a drug (hydrophilic or hydrophobic), their surface polarity character (compared to un-loaded ones) in medium might change due to the nature of the drug and the effect caused by the encapsulated or free (un-encapsulated) drug on the surfaces,<sup>87</sup> which might in turn have an effect on drug delivery. Therefore, depending on the drug encapsulated or adsorbed in SNPs, the degree of wetting ability of SNPs or the hydrophilic/



**Fig. 3** Functionalisation of SNPs with octadecyl methyl groups reduced their hydrophilicity. (A) The change in contact angle for SNPs SP with/without various functional groups at different time intervals, showing increase of hydrophobicity in SNPs SP functionalised with octadecyl methyl groups. (B) The change in contact angle for SNPs LP with/without various functional groups at different time intervals, showing increase of hydrophobicity in SNPs LP functionalised with octadecyl methyl groups.



hydrophobic interaction with the medium can change which would have an implication in the delivery of the drug. Although the *in vitro* release medium or a physiological medium in intestines is different from DW that we used in contact angle measurements, it was very important to investigate how the contact angles might change when the SNPs-CH<sub>3</sub> were loaded with Van. Fig. 3 and Fig. S12, S13 (ESI<sup>†</sup>) shows the time-lapse contact angles measured for Van-loaded SNPs-CH<sub>3</sub>. As can be seen, SNPs-CH<sub>3</sub> loaded with Van showed a slight reduction of contact angles compared to their corresponding un-loaded SNPs-CH<sub>3</sub>, possibly due to the influence that Van on the surfaces might have had (note: there was no change of contact angles for hydrophilic SNPs loaded with Van compared to their un-loaded counterparts, data not shown). Van-loaded SNPs LP-CH<sub>3</sub> showed a more noticeable change of contact angle over time. In comparison to Van-loaded SNPs SP-CH<sub>3</sub>, although SNPs SP-CH<sub>3</sub> loaded with Van showed a slight reduction of contact angles initially, the contact angle value became roughly constant over 4 minutes. This might indicate that there might have been Van on the SNPs surfaces which initially reduced slightly the contact angles (since Van is a hydrophilic molecule) once the water droplet fell on the surface but as time went the hydrophobic nature of octadecyl methyl groups contributed and overcame the initial slight decrease hence the contact angle values remained almost constant.

**3.4.2. Surface chemistry and elemental analyses.** The data presented above including size and morphology, surface area and porosity, surface charge and polarity showed that different functional groups were successfully functionalised on SNPs, which was also confirmed in FTIR and TGA data. However, grafting of functional groups during synthesis may occur either on the outside surfaces of SNPs or on the surfaces inside the pores. On the latter, with porosity data we confirmed that the pore size and distribution somewhat decreased upon functionalisation, which shows that the functional groups might have

anchored on the surfaces inside the pores. Although we confirmed that the functional groups were also grafted on the outside surfaces of SNPs (by investigating the surface charge and hydrophilic/hydrophobic properties of SNPs) it was important to perform XPS measurements to better understand and quantify more precisely the elemental chemical composition on the outermost surfaces of SNPs and to elucidate the nature of the surfaces of functionalised SNPs. XPS has been demonstrated to be a unique, sensitive quantitative (for all elements except H and He), and powerful tool for characterizing the surface chemical structure of nanomaterials since it is non-destructive and provides chemical analysis of the outermost (approximately 5–8 nm, near surface region of the material) surfaces of the material.<sup>88,89</sup>

The wide scan XPS spectra of un-functionalised SNPs (Fig. 4) revealed three distinctive bands at a binding energy of 531.0, 151.0, and 102.0 eV, which corresponded to O 1s, Si 2s, and Si 2p, respectively, and there was no noticeable difference between SNPs SP and SNPs LP in terms of their elemental compositions on the surfaces (Table S14, ESI<sup>†</sup>). Even if the high-resolution XPS spectra of O 1s, Si 2s, and Si 2p were not carried out, those bands and binding energies can be associated with bonds of Si–O–Si and Si–OH, showing a silica network with silanol groups on the surface of SNPs. XPS spectra of functionalised SNPs are also presented in Fig. 4. From the figure, SNPs (SP and LP) functionalised with –NH<sub>2</sub> showed the bands of O 1s, Si 2s, and Si 2p similar to un-functionalised ones but with additional bands at a binding energy of 282.0 and 397.0 eV, which were attributed to C 1s and N 1s, respectively, showing that aminopropyl groups from APTES were successfully functionalised on the SNPs surfaces. Looking at their elemental composition (%) (Table S14, ESI<sup>†</sup>), it can be seen that SNPs LP-NH<sub>2</sub> has a slightly higher composition of C 1s and N 1s adsorbed on their surfaces compared to SNPs SP-NH<sub>2</sub> (19.84 vs. 17.63% for C 1s and 3.69 vs. 2.39% for N 1s), which




Fig. 4 Wide scan XPS spectra of un-functionalised and functionalised SNPs. (A) SNPs SP with/without different functional groups and (B) SNPs LP with/without different functional groups.

would be ascribed to higher surface area of SNPs LP (discussed in Section 3.2) where more groups might have been attached in comparison to SNPs SP. Although these surface elemental composition (%) results for SNPs-NH<sub>2</sub> concur with TGA data, we do not see any positive correlation with SNPs-NH<sub>2</sub> surface charge data and this indicates that other parameters like pore sizes of SNPs-NH<sub>2</sub> might have involved.<sup>74</sup> For SNPs-PO<sub>3</sub> functionalisation, the surveyed XPS spectra exhibited four peaks at 531.0, 282.0, 151.0 and 102.0 eV representing the binding energies of O 1s, C 1s, Si 2s and Si 2p, respectively. The presence of C 1s in the spectrum suggested that propyl methyl-phosphonate groups were successfully functionalised on SNPs (since un-functionalised SNPs did not show C 1s in their XPS spectra and this was not due to contamination). The absence of phosphorus in the spectrum indicates that if P was present, it was at concentrations below the detection limit of the XPS (generally 0.1–1 atom %).<sup>90</sup> Moreover, C 1s elemental composition was also slightly lower in SNPs SP-PO<sub>3</sub> compared to SNPs LP-PO<sub>3</sub> (7.49% vs. 8.74%), which might be due to surface area (as mentioned above). The XPS spectra scans of -CH<sub>3</sub> functionalised SNPs also showed the peak of C 1s which is associated with octadecyl methyl groups anchored to the SNPs surfaces. Regarding the % composition of C 1s in SNPs-CH<sub>3</sub> (Table S14, ESI<sup>†</sup>), SNPs SP-CH<sub>3</sub> has almost four-fold the amount of C 1s compared to SNPs LP-CH<sub>3</sub> (58.33% vs. 15.76%), which can also be correlated with their corresponding TGA and porosity data. This shows that unlike functionalisation with -NH<sub>2</sub> and -PO<sub>3</sub>, the higher surface area of SNPs LP did not help increase the degree of grafting of octadecyl methyl silanes on SNPs. Also, since condensation may occur during synthesis, it is difficult to exclude the possibility that some of the C 1s might

also arise from the condensed and/or un-adsorbed octadecyl silanes, although multiple washing steps were done to ensure the complete removal of un-grafted ODMs.

### 3.5. Loading of Van in SNPs

Van (30% w/w theoretical loading) was initially loaded into un-functionalised and functionalised SNPs and TGA was used to determine the loading capacity of Van. The loading capacity of Van into un-functionalised SNPs was ca. 25 wt% (Fig. 5A), with SNPs SP and SNPs LP showing no impact of pore size on the loading capacity. However, the loading capacity of functionalised SNPs did differ depending on the functional groups used (Fig. 6). For functionalised SNPs SP, the Van loading was slightly higher than un-functionalised SNPs SP, at about 29 wt% and 28 wt%, respectively for SNPs SP functionalised with -NH<sub>2</sub> and -PO<sub>3</sub>. In contrast, Van loading decreased significantly to approximately 18 wt% for SNPs SP-CH<sub>3</sub>, showing that the surface area and hydrophobic modification impacted the Van loading. For functionalised SNPs LP, Van loading was around 29 wt% for all the samples, which demonstrates that despite functionalising the SNPs successfully, SNPs pores were not blocked, and thus Van loading was not affected. Moreover, in comparison to the Van loading capacity of un-functionalised SNPs these results suggest that the functionalization of the surface of SNPs might have reduced the pore size and increased the interactions forces between Van and matrix mesoporous surfaces and hence higher loading capacity.<sup>91</sup> However since the physisorption of the drug on SNPs is a surface phenomenon and it would depend on the surface area of the SNPs where the drug can physically adsorb,<sup>91</sup> the significant reduction of surface area in the case of SNPs SP-CH<sub>3</sub> might have impacted




Fig. 5 (A) TGA of SNPs SP-Van and SNPs LP-Van. (B) FT-IR spectra of pure Van, SNPs SP-Van, and SNPs LP-Van. (C) XPS survey spectra of SNPs SP-Van and SNPs LP-Van.




Fig. 6 TGA of (A) SNPs SP-NH<sub>2</sub> loaded with Van, (B) SNPs SP-PO<sub>3</sub> loaded with Van, (C) SNPs SP-CH<sub>3</sub> loaded with Van, (D) SNPs LP-NH<sub>2</sub> loaded with Van, (E) SNPs LP-PO<sub>3</sub> loaded with Van, and (F) SNPs LP-CH<sub>3</sub> loaded with Van.

negatively the adsorption of Van since there was not enough space on the SNPs SP-CH<sub>3</sub> surfaces for Van to physically adsorb or the hydrophobic nature of SNPs SP-CH<sub>3</sub> might contribute to repel Van. The loading of Van into the mesopores of SNPs was further confirmed by N<sub>2</sub> adsorption/desorption measurement. The loading of Van in SNPs leads to a decreased BET surface area and pore volume (Table 3). For example, BET surface area decreased from 411.50 and 623.87 m<sup>2</sup> g<sup>-1</sup> (for SNPs SP and SNPs LP, respectively) to 118.26 m<sup>2</sup> g<sup>-1</sup> and 251.17 m<sup>2</sup> g<sup>-1</sup> after being loaded with Van. Similarly, the pore volume was markedly reduced from 0.583 cm<sup>3</sup> g<sup>-1</sup> and 1.343 cm<sup>3</sup> g<sup>-1</sup> for SNPs SP and SNPs LP, respectively to 0.1 m<sup>3</sup> g<sup>-1</sup> and 0.26 m<sup>3</sup> g<sup>-1</sup> after being loaded with Van, which indicates the entrapment and presence of Van molecules in the pores.

Furthermore, FTIR was performed for Van-loaded SNPs and the results are presented in Fig. 5B. The characteristic spectral bands of pure Van (Fig. 5B, 1st spectrum from up) were aromatic C=C at 1651 cm<sup>-1</sup>, C=O stretching vibrations associated with amino groups at 1503 cm<sup>-1</sup>, C-C bending vibrations in aromatic rings at 1400 cm<sup>-1</sup>, Ar-O-Ar at 1227 cm<sup>-1</sup>, and C-H bending vibration at 1064 cm<sup>-1</sup>. FTIR

spectra of SNPs loaded with Van showed both vibrational characteristics of Van and SNPs. The bands associated with chemical groups (at 1651, 1503, 1400 cm<sup>-1</sup>) of Van appeared in the spectra of Van-loaded SNPs, which demonstrated that Van has been loaded into SNPs, although the peaks associated with Van (Ar-O-Ar and C-H bending vibrations in the region of 1250–900 cm<sup>-1</sup>) are not observed due to the substantial peak from the big Si-O-Si asymmetric stretching band in that region which masks the eventual contribution of Van peaks in that same region. In addition, some changes in the shape and intensity of FTIR bands of SNPs in Van-loaded SNPs were noticed compared to un-loaded SNPs spectra (Fig. 5B, 1st and 2nd spectra from bottom). For instance, compared to un-loaded SNPs, the sharp peaks of the Si-O-Si asymmetric stretching band (at 1072 cm<sup>-1</sup>), symmetric stretching of Si-O-Si (at 798 cm<sup>-1</sup>), and Si-O-Si bending vibration (451 cm<sup>-1</sup>) became slightly wider when loaded with Van, suggesting that Van loading did affect those SNPs IR peaks, probably due to weak intermolecular interactions between Van molecules and SNPs. Van was also processed alone (without SNPs) to see whether the loading method used had an impact on the chemical structure

Table 3 Surface charge, particle characteristics, and surface area of Van-loaded SNPs

Van-loaded SNPs	Surface charge (mV)	Mean particle size (nm) ± SD		Polydispersity index (PDI) ± SD		BET surface area [m <sup>2</sup> g <sup>-1</sup> ]	Pore volume [cm <sup>3</sup> g <sup>-1</sup> ]
		Van-loaded SNPs <sup>a</sup>	Un-loaded SNPs <sup>b</sup>	Van-loaded SNPs	Un-loaded SNPs		
SNPs SP-Van	-24.6 ± 1.08 <sup>e</sup>	230 ± 79 <sup>a,c</sup>	130 ± 40 <sup>b,d</sup>	0.33 ± 0.02	0.28 ± 0.03	118.26	0.1
SNPs LP-Van	-21.53 ± 2.15 <sup>e</sup>	273 ± 49 <sup>a,c</sup>	153 ± 37 <sup>b,d</sup>	0.39 ± 0.03	0.37 ± 0.03	251.17	0.26

<sup>a,b</sup>Unpaired two tailed *t* test was performed and there was a significant difference in particle size of samples in *a* in comparison to samples in *b* and the values with different letter in the same row are significantly different ( $p < 0.05$ ). <sup>c</sup>Indicates the significant difference ( $p < 0.05$ ) in particle size in comparison to un-functionalised SNPs presented in Table 1. <sup>d</sup>Indicates that there was no significant difference ( $p > 0.05$ ) in particle size in comparison to un-functionalised SNPs presented in Table 1. <sup>e</sup>Indicates that there was no significant difference ( $p > 0.05$ ) in surface charge in comparison to un-functionalised SNPs presented in Fig. 2.

of Van, and FTIR spectrum of processed Van (Fig. 5B, 2nd spectrum from up) showed similar spectrum as of pure Van indicating that the FD process did not affect the chemical structure of Van.

In addition, the presence of Van in SNPs was revealed from the comparison of chemical analysis through XPS measurements of Van-loaded SNPs, as shown in Fig. 5C. The binding energy peaks of N 1s (397 eV) were observed at the survey scan of Van-loaded SNPs. This shows the presence of nitrogen-containing groups in Van-loaded SNPs, which are the typical fingerprint groups of Van molecules and are not found in unloaded SNPs. C 1s peaks (282 eV) were also present in Van-loaded SNPs confirming the presence of Van. Moreover, the elemental composition (%) was different for both SNPs SP-Van and SNPs LP-Van. For instance, SNPs SP-Van showed higher composition (%) of C 1s and N 1s compared to SNPs LP-Van (21.31 vs. 11.58% for C 1s and 1.89 vs. 1.48 for N 1s), although they both had approximately the same loading capacity. This difference in XPS elemental composition can be explained by looking into the morphology and structure of their pores. While SNPs SP had smaller and superficial pores, SNPs LP had bigger, deep, and channel-like pores, which are symmetric around the core (as we discussed above). So, in the case of SNPs SP, more Van might have adsorbed on the surfaces and in the pores which might have been accessible to be detected by XPS (which is specific for surface analysis, around 5 nm of depth). On the other hand, with SNPs LP more Van might have penetrated deeply into the channel-like pores of SNPs LP (deeper than the detection depth of XPS) during the loading process and hence the amount of Van to be detected by XPS on the surface was lower compared to SNPs SP therefore lower % of C 1s and N 1s for SNPs LP-Van.

To investigate the particle size characteristics of SNPs-Van, SNPs after release studies were collected from the dialysis bag and analysed by DLS for their particle size characteristics. As shown in Table 3, after Van release studies in pH simulated intestinal medium, the mean measured particle sizes of SNPs SP and SNPs LP increased significantly to  $230 \pm 79$  and  $273 \pm 49$  nm, respectively, compared to unloaded ones (un-functionalised SNPs in Table 1), suggesting that released Van—at least in this study—might have somewhat bound to SNPs after diffusion from the pores and increased the particle

size (although Van is hydrophilic and we kept sink conditions during release studies). To investigate whether it was the influence of release medium (compared to DW used as dispersion medium in DLS), the un-functionalised and un-loaded SNPs were dispersed in release medium for 10 h and were subsequently analysed by DLS. As it can be seen in Table 3, the mean particle sizes of SNPs SP and SNPs LP were  $130 \pm 40$  and  $153 \pm 37$  nm, which were not significantly different from the ones in Table 1, showing that the particle size characteristics were affected by Van loading but not by the release medium. In addition, the surface charge values of SNPs after Van release (Table 3) were not significantly different from the values of unloaded SNPs (in Fig. 2), showing that the Van loading did not significantly alter the surface charge of SNPs under the release conditions (pH 6.8) despite Van containing ionizable groups (one carboxyl, two amino, and three phenolic).<sup>92</sup> Here in the solution with pH of 4 Van is slightly cationic (with net molecular charge of +2). However, when the pH of the medium increases the net molecular charge slightly decreases and it reaches net molecular charge of zero at around pH of 7.0<sup>92</sup> and that's probably the reason why in the release medium of 6.8, the surface charge of Van-loaded SNPs were not significantly altered.

### 3.6. *In vitro* release studies of Van-loaded SNPs

The release behaviour of the drug is a crucial parameter for the controlled and sustained delivery of therapeutics.<sup>93</sup> For antibiotics, the effectiveness of different antibiotic is driven by different pharmacokinetic parameters, such as the maximum concentration, the time at which the concentration is above the MIC, or the area under the curve.<sup>94</sup> The influence of the SNPs and their functionalisation on the release behaviour of Van in response to pH conditions similar to the small intestine was investigated and the release profiles are presented in Fig. 7.

Regardless of whether Van was loaded in un-functionalised or functionalised SNPs, Van-loaded SNPs showed a more prolonged release than pure (un-encapsulated Van) (Fig. 7A and B). For instance, the initial dissolution and release rate of pure Van was higher with  $82 \pm 2.4\%$  of Van being released within first 40 min. In comparison, Van-loaded SNPs SP and Van-loaded SNPs LP showed a relatively slower release with a cumulative release of  $36 \pm 2.3\%$  and  $16 \pm 1\%$ , respectively, in 40 min




Fig. 7 Release profiles of (A) Van-loaded SNPs SP, (B) Van-loaded SNPs LP, and (C) processed Van and Van SNPs produced by physically mixing them at a specified ratio. The error bars on the graphs represent the ( $n = 3 \pm \text{SD}$ ).



(Fig. 7A and B, red lines) and this was 2.3 and 5.1 times less in comparison to percentage release of pure Van. This initial release pattern for Van-loaded SNPs indicates that although there might have been Van on the surfaces of SNPs, Van was either adsorbed (by physisorption) on the SNPs surfaces or in low amount since we do not see a burst release of Van (due to rapid dissolution of free Van on the surfaces) especially in the first 20 min. Moreover, looking at the release patterns it is evident that the release pattern of pure Van (as time progressed) was different from that of Van-loaded SNPs. For instance, after reaching a  $90 \pm 0.3\%$  cumulative release within 80 min, as time progressed the release rate of pure Van slightly declined and almost plateaued. In contrast, the cumulative amount of released Van from SNPs over time kept increasing in a more linear and quadratic manner, exhibiting a steady-state flux with for example  $50 \pm 4.4\%$  and  $41 \pm 1.5\%$  cumulative release of Van from SNPs SP-Van and SNPs LP-Van, respectively, within 80 min. This sustained and more linear release pattern of Van from SNPs compared to pure (un-encapsulated) Van could be due to the entrapment of Van inside the pores and/or adsorption onto the SNPs surfaces, which results in a longer time for Van to be diffused from inside the pores to the release medium. Although we did not perform *in vivo* release studies and although there are many other factors which can impact the Van release behaviour *in vivo*,<sup>95</sup> these results suggest a more controlled release of Van from SNPs compared to pure Van which could be beneficial in reducing the dosage frequency of Van in case of Van-loaded SNPs based formulations.<sup>96</sup> Regarding the type of SNPs (SNPs SP or SNPs LP), there was a slight difference in their release profiles where release rate of Van from SNPs LP was slightly lower than that from SNPs SP (red line in Fig. 7A vs. red line in Fig. 7B). This might be attributed to the fact that Van in SNPs LP was loaded and trapped deeply in the channels of SNPs LP and thus it took longer to be accessed by release medium whereas Van in SNPs SP was adsorbed in the more superficial pores.

When the Van-loaded un-functionalised SNPs were compared to Van-loaded functionalised SNPs, there were slight differences in their release rates. For instance, compared to un-functionalised SNPs loaded with Van, within first 4 h the cumulative release of Van in SNPs LP-NH<sub>2</sub> was slightly higher in comparison to SNPs LP-Van (Fig. 7B, blue line vs. red line) although the difference was not remarkable in SNPs SP. In SNPs-PO<sub>3</sub>, regardless of pore size, the cumulative release of Van was slightly lower throughout the time of release compared to SNPs LP-Van (Fig. 7A and B, green line vs. red line). In comparison to un-functionalised SNPs, SNPs-NH<sub>2</sub> and SNPs-PO<sub>3</sub>, the SNPs-CH<sub>3</sub> showed a substantially slower Van release throughout 10 h release (Fig. 7A and B, maroon line vs. other lines), suggesting that hydrophobic modification was more effective in retarding Van release compared to hydrophilic functional groups. Here when SNPs-CH<sub>3</sub>-Van were suspended in release medium they might self-aggregate and form a cluster-like structure due to their surface hydrophobicity, blocking the release of Van from the pores.

When drug is loaded in SNPs or in any carrier, the process used not only helps to load or adsorb the drug of interest, but it also impact the drug characteristics.<sup>11</sup> Drug solid state, particle size and other characteristics may be altered, which can consequently have an impact on release behaviour.<sup>11,97</sup> It is therefore important to understand that the way the drug dissolves and releases from carriers might be the result of (1) the drug being adsorbed and/or encapsulated in the carrier (SNPs in this case) and/or (2) the impact of process on the drug itself. Therefore, we investigated the processed Van (alone) to assess whether there was any possible impact of the process on Van. The FTIR data of pure Van and processed Van were similar, which shows that the process did not change the molecular structure of Van (Fig. 5B). Similarly, the release behaviour of processed Van was not different from that of pure Van (Fig. 7C), confirming that the release behaviours in Fig. 7A and B were due to the Van encapsulation and/or adsorption in mesopores of SNPs and not the impact of the FD process.

As discussed earlier, the slow-release behaviour of Van-loaded SNPs is proposed to be due to Van that is loaded and trapped and/or adsorbed into the pores is slowly released compared to free drug. To ensure that simple mixing of Van and SNPs without any processing did not lead to the same impact on the release behaviour of Van, we tested the release profiles of Van-loaded SNPs prepared by physical mixture. As shown in Fig. 7C they showed no difference in comparison to pure Van, confirming that the slow-release behaviour of Van-loaded SNPs was due to the entrapment and adsorption of Van molecules into the pores of the SNPs.

### 3.7. *In vitro* cytotoxicity assays


The cytotoxicity assays for SNPs in Caco-2 cells were performed by MTT assay. SNPs (functionalised/un-functionalised) in different concentrations ranging between 25–500  $\mu\text{g mL}^{-1}$  were studied for their cytocompatibility in Caco-2 cells. The results are shown in Fig. S15 (ESI<sup>†</sup>). A slight decrease of cell viability is seen compared to controls, with a slight concentration-dependent cytotoxic effect evident for SNPs-CH<sub>3</sub>, but not other SNPs. Overall, more than 80% cell viability was observed for all the SNPs in the concentration range tested, suggesting a lack of cytotoxicity on Caco-2 cells. This concurs with previous studies about the *in vitro* cytotoxicity of mesoporous silica nanomaterials.<sup>55,98</sup>

### 3.8. Permeability studies of Van-loaded SNPs

**3.8.1. Effect of SNPs on the permeability of Van across Caco-2 cell monolayers.** When the drug is delivered orally, to reach the lamina propria and then to systemic circulation, drug must permeate the intestinal epithelium from the apical to the basolateral side.<sup>11</sup> While other physiological factors can affect the *in vivo* oral bioavailability of drug especially,<sup>11</sup> the apparent permeability ( $P_{\text{app}}$ ) values of the drug have shown to correlate with their bioavailability.<sup>64,99</sup> The permeability of Van-loaded SNPs was investigated in Caco-2 cell model, the most common *in vitro* model for intestinal transport studies.<sup>100,101</sup> Caco-2 cells are used in transport experiments due to their morphological

and functional characteristics resembling enterocytes (they express microvilli, comparable tight junctions, and several enzymes and transporters<sup>102,103</sup>). All Van-loaded SNPs (except Van-loaded SNPs-CH<sub>3</sub>) showed a significant enhancement of permeability of Van in comparison to pure (un-encapsulated) Van (Fig. 8). For example, the cumulative amount of permeated Van (% of permeated amount in respect to the initial amount) after 3 h (Fig. 8A) ranged between  $2.57 \pm 0.15$ – $3.62 \pm 0.29\%$  for SNPs SP and  $5.92 \pm 0.22$ – $6.92 \pm 0.31\%$  for SNPs LP, which was significantly higher than pure Van (only  $1.23 \pm 0.18\%$ ). Also, the  $P_{app}$  values (Fig. 8B) were significantly increased from  $0.304 \times 10^{-5} \text{ cm s}^{-1}$  (for pure Van) to values ranging between  $0.637 \times 10^{-5} \text{ cm s}^{-1}$  and  $0.898 \times 10^{-5} \text{ cm s}^{-1}$  for SNPs SP and  $1.468 \times 10^{-5} \text{ cm s}^{-1}$  to  $1.716 \times 10^{-5} \text{ cm s}^{-1}$  for SNPs LP, a 2- to 6-fold enhancement in  $P_{app}$  in comparison to pure Van (Fig. 8C). This enhancement of permeability of Van-loaded SNPs compared to pure Van is likely due to SNPs-mediated transient opening of the tight junctions of Caco-2 cell monolayers, as previously reported in the literature.<sup>30,104</sup> Generally, the modulation of paracellular transport is governed and regulated by the tight junctions. Tight junctions consist of transmembrane proteins such as occludins and claudins, and cytoplasmic proteins, which tie the transmembrane proteins to the apical actin–myosin ring and maintain the integrity and selective permeability of intestinal epithelium.<sup>105–107</sup> The permeability of peptide therapeutics (Van in this case) or other biologics by SNPs is increased when SNPs manage to partition and transiently disrupt those tight junctions.<sup>30,104,108</sup> However, the involvement of other SNP-mediated mechanisms (like endocytosis and exocytosis)<sup>30,109</sup> or even the combination of different transport mechanisms cannot be ruled out. While beyond the scope of this paper, additional studies to elucidate the mechanism(s) that might be involved in the SNPs enhancement of Van permeation are needed.

Moreover, pore size (SNPs SP or SNPs LP) and morphology had substantial effects on the permeability of Van (Fig. 8A–C). Van-SNPs SP and Van-SNPs LP showed different trends in terms of permeated amount of Van (Fig. 8B) and  $P_{app}$  profiles (Fig. 8B). For example, at 3 h (Fig. 8B), the  $P_{app}$  values increased significantly from  $0.826 \times 10^{-5} \text{ cm s}^{-1}$ ,  $0.637 \times 10^{-5} \text{ cm s}^{-1}$ , and  $0.898 \times 10^{-5} \text{ cm s}^{-1}$  for SNPs SP, SNPs SP-NH<sub>2</sub>, and SNPs SP-PO<sub>3</sub>, respectively, to  $1.716 \times 10^{-5} \text{ cm s}^{-1}$ ,  $1.468 \times 10^{-5} \text{ cm s}^{-1}$ , and  $1.622 \times 10^{-5} \text{ cm s}^{-1}$  when their SNPs LP counterparts were tested, and that was consistently more than a 2-fold increase in  $P_{app}$  for SNPs LP in comparison to SNPs SP (Fig. 8C). In addition to the fact that pore size and morphology might have played a crucial role,<sup>110</sup> the degree of Van adsorption on the SNPs (SNPs LP vs. SNPs SP) might have played a significant role too. Our hypothesis here is that even if there was no significant difference in the loading capacity between SNPs SP and SNPs LP, a high amount of Van might have been encapsulated and adsorbed deep in the channel-like pores of SNPs LP, whereas in the case of SNPs SP a high amount of Van might have been in the superficial small pores of SNPs or even free on the surfaces (as discussed in detail in Section 3.6). Why does this matter? Well, as we discussed above, SNPs disrupt and open the tight junctions and then the drug is carried through the epithelium and reach the basolateral chamber. At this point we do not know which Van permeation mechanism is involved. Does the Van diffuse and release from SNPs first and then permeate (free without SNPs) *via* the already open tight junctions to reach the basolateral chamber? If this was the case, then Van-SNPs from PM (physical mixture) should have shown improved permeability compared to pure Van, which was not the case ( $P_{app}$  value of Van-SNPs LP was not significant different from pure Van, Fig. 8C). Based on the data, our hypothesis is that the SNPs open the tight junctions and then they act as delivery vehicles to carry Van across the epithelium and shuttle the Van payload to the receiving chamber. Correlating this with



**Fig. 8** SNPs (functionalised or un-functionalised, except SNPs-CH<sub>3</sub>) significantly increased the permeability of Van across Caco-2 cells monolayers. All the values in the figure are presented as means  $\pm$  SDs of  $n \geq 3$ . (A) Cumulative permeability profiles of Van-loaded SNPs in Caco-2 cell monolayers for 3 h period. (B) Apparent permeability ( $P_{app}$ ) of Van-loaded SNPs across Caco-2 cell monolayers; statistical variance among the samples was analysed by one-way ANOVA, followed by Tukey's test for multiple comparisons; ns: no significance; significance level was  $*p < 0.033$ ,  $**p < 0.002$  and  $***p < 0.0002$  with respect to pure Van; <sup>s</sup> indicates the significant increase of  $P_{app}$  for Van-loaded SNPs in comparison to pure Van; <sup>££</sup> Van-loaded SNPs-CH<sub>3</sub> showed no improvement of  $P_{app}$ , in fact SNPs-CH<sub>3</sub> reduced significantly the  $P_{app}$  of Van in comparison to pure Van. (C) Enhancement ratio (ER) of the apparent permeability ( $P_{app}$ ) of Van from different SNPs (at 3 h); ER was determined using the following equation:  $ER = P_{app, \text{Van-loaded SNPs}} / P_{app, \text{pure Van}}$ ; also, un-paired two tailed *t*-test was performed to analyse the statistical variance for each sample vs. pure (un-encapsulated) Van; significance level was <sup>££</sup> $p < 0.002$ , <sup>£££</sup> $p < 0.0002$  and <sup>££££</sup> $p < 0.0001$ . Van-loaded SNPs LP produced by physical mixture was also studied and compared to pure Van.

different ways Van might have been encapsulated and/or adsorbed in SNPs LP compared to SNPs SP, it might have happened that the high amount of free and superficially adsorbed Van in SNPs SP might have diffused, released, and deposited in the apical chamber and hence even if SNPs SP might have reached the basolateral chamber, the high amount of Van might have already been released and deposited in the apical chamber. On the other hand, Van in SNPs LP are entrapped and adsorbed in their deep channel-like pores which does not allow Van to quickly be diffused and deposited in the apical chamber. Therefore, in the latter, the SNPs LP are able to carry the Van payload *via* the epithelium and shuttle Van in the basolateral compartment hence the Van permeability in SNPs LP is higher than SNPs SP. This explanation is based on the permeability data but if we correlate these data with release studies, we see that although SNPs SP (un-functionalised/hydrophilically functionalised) showed slightly higher release at 3 h compared to SNPs LP counterparts, the difference was not significant in all the samples.

In addition to pore size, SNPs surface chemistry had a significant effect on Van permeability. Initially our hypothesis was that altering the SNPs surfaces charge and polarity by functionalising them with different groups would influence the permeability behaviours of Van. Irrespective of pore size, SNPs functionalised with  $-\text{NH}_2$  showed lower  $P_{\text{app}}$  values compared to SNPs- $\text{PO}_3$  or un-functionalised SNPs. For example (at 3 h), the value of  $P_{\text{app}}$  was significantly ( $p > 0.05$ ) reduced from  $1.716 \times 10^{-5} \text{ cm s}^{-1}$  and  $1.622 \times 10^{-5} \text{ cm s}^{-1}$ , respectively, for SNPs LP (un-functionalised) and SNPs- $\text{PO}_3$  to  $1.468 \times 10^{-5} \text{ cm s}^{-1}$  for SNPs LP- $\text{NH}_2$ . This reduction in  $P_{\text{app}}$  value for  $-\text{NH}_2$  functionalised SNPs can be attributed to the fact that there might have a strong electrostatic interactions between the cationic SNPs- $\text{NH}_2$  and the negatively charged cellular membranes<sup>111</sup> and this did not permit the Van-loaded SNPs- $\text{NH}_2$

to easily carry the Van across the epithelium to basolateral compartment. Moreover, the polarity of SNPs significantly affected the permeability of Van. For Van-loaded SNPs- $\text{CH}_3$  (either SNPs SP or SNPs LP), the Van permeability was not only remarkably lower compared with other Van-loaded SNPs but also it was significantly low in comparison to pure Van, with only  $0.015 \times 10^{-5} \text{ cm s}^{-1}$  and  $0.044 \times 10^{-5} \text{ cm s}^{-1}$  for Van-loaded SNPs SP- $\text{CH}_3$  and Van-loaded SNPs LP- $\text{CH}_3$ , respectively, at 3 h. This might have been due to the hydrophobic nature of SNPs- $\text{CH}_3$ , where the diffusion, release, and dissolution of Van in the incubation media might have hindered by the hydrophobic nature of SNPs- $\text{CH}_3$ , although we cannot entirely attribute this to their release behaviours. Furthermore, as we discussed above, SNPs disrupt and transiently open the tight junctions, which allow the drug to be carried to the basolateral chamber and this has been shown to correlate well with TEER values (the reduction of TEER values indicates the disruption, relaxation, and/or opening of tight junctions and *vice versa*) especially for molecules with size from 180 Da to at least 10 kDa.<sup>112,113</sup> By correlating this with our results for example, as you can see from the Fig. 8, for the first 2 h of experiment, there was no amount (0%) of Van permeated from Van-SNPs- $\text{CH}_3$ . The question here is why SNPs- $\text{CH}_3$  still showed significant reduction of TEER values in the first 2 h (Fig. S16, ESI<sup>†</sup>) despite 0% of Van permeation in the basolateral chamber? Our hypothesis here is (1) Van-loaded SNPs- $\text{CH}_3$  were able to transiently open the tight junctions, and to traverse across the epithelium to reach the basolateral chamber, but as they are hydrophobic in nature, encapsulated and/or adsorbed Van was not able to be diffused and released (in 1 h or 2 h, even if 1% DMSO was used as a co-solvent and although their release profiles show that they can be in this time frame); (2) since SNPs- $\text{CH}_3$  are hydrophobic, they were able to bind and fuse with cell membrane phospholipid bilayers (as we initially hypothesized), hence the disturbance of tight junctions and TEER values decrease



**Fig. 9** The ability of SNPs to disrupt the integrity of Caco-2 cell monolayers and whether the effect is reversible was investigated by treating the Caco-2 cell monolayers with Van-free (A) SNPs SP (functionalised/un-functionalised) and (B) SNPs LP (functionalised/un-functionalised) for 3 h. After 3 h of treatment, SNPs were removed, and the Caco-2 cell monolayers were rinsed with DMEM and equilibrated, and their recovery was studied within the next 24 h. TEER<sub>0</sub> means TEER ( $\Omega \text{ cm}^2$ ) values at initial time point ( $t = 0$ ). TEER values are presented as means  $\pm$  SDs ( $n = 3$ ) considering the TEER values of untreated Caco-2 cells (Caco-2 cell monolayers with only HBSS or HBSS + 1% DMSO without SNPs, N.B.: we wanted to assume that DMSO might have an impact on the Caco-2 cell monolayers integrity, so we performed experiments by dosing the apical chamber with 0.5 mL of HBSS containing 1% DMSO and there was no significant difference in TEER values in comparison to DMSO-free HBSS). Statistical variance among the samples was analysed by one-way ANOVA, followed by Tukey's test for multiple comparisons. \*indicates the significant difference ( $p < 0.05$ ) in TEER values (throughout treatment experiment) between SNPs- $\text{CH}_3$  vs. other samples, & indicates the significant difference ( $p < 0.05$ ) in all the samples, # indicates the significant difference ( $p < 0.05$ ) between SNPs LP- $\text{NH}_2$  and SNPs- $\text{PO}_3$ , \$ indicates that there was no significant difference ( $p > 0.05$ ) between SNPs LP and SNPs LP- $\text{PO}_3$ , @ indicates the significant difference ( $p < 0.05$ ) between SNPs LP- $\text{NH}_2$  and SNPs- $\text{CH}_3$ , & indicates the significant difference ( $p < 0.05$ ) (SNPs LP and SNPs LP- $\text{PO}_3$  vs. SNPs LP- $\text{NH}_2$  and SNPs- $\text{CH}_3$ ).

but they stuck either in the phospholipid bilayers of cytoplasmic membrane or in the cytoplasm and were not able to escape and/or transcytose across the cytoplasm to reach the basolateral compartment. Whether we consider the first hypothesis or second the detailed investigation, elucidating which Caco-2 cells monolayers-SNPs-CH<sub>3</sub> interaction mechanism is involved, is needed.

**3.8.2. Reversible effect of SNPs on TEER.** We studied the effect of SNPs on the integrity and the change in TEER values of Caco-2 cell monolayers during treatment and post-treatment to see whether the effect of SNPs on Caco-2 epithelium was reversible (whether the monolayers are restored). After 3 h of treatment with Van-free SNPs, Caco-2 cell monolayers were rinsed twice with pre-conditioned DMEM and equilibrated and then 0.5 mL and 1.5 mL of DMEM was placed in apical and basolateral compartment, respectively, and the Caco-2 cell monolayers recovery experiments were done for the next 24 h. The TEER values were measured during the treatment and recovery experiment, as presented in Fig. 9. From the figure, it can be seen that all SNPs led to a significant drop in TEER values within the first 30 min of treatment and TEER decrease was significantly higher ( $p > 0.05$ ) in hydrophilic SNPs compared with hydrophobic SNPs-CH<sub>3</sub>. Moreover, SNPs showed distinctive patterns throughout recovery period. For example, within 4 h period of the recovery experiment, while TEER values for other SNPs start to slightly increase, the TEER values for SNPs-CH<sub>3</sub> kept decreasing. Also, there was a slight difference in recovery profiles of anionic compared to cationic SNPs, where the recovery rate for SNPs-NH<sub>2</sub> was slightly lower than the anionic SNPs throughout the recovery period. For example, SNPs SP-NH<sub>2</sub> and SNPs LP-NH<sub>2</sub> showed only  $88.72 \pm 4.63\%$  and  $90.22 \pm 2.51\%$  recovery, respectively, within 12 h, whereas within that time all anionic SNPs (including SNPs-CH<sub>3</sub>) showed full TEER recovery. Nevertheless within 24 h of recovery experiment, all Caco-2 cell monolayers exhibited full TEER recovery, which indicates that SNPs induced a reversible effect on Caco-2 cell epithelial monolayers, with an enhancement of the permeability of Van, without permanently disrupting the integrity of Caco-2 cell monolayers.

## 4. Conclusion

The oral delivery of Van has the potential to improve disease outcomes and patient experience by alleviating the drawbacks associated with Van injections. Unfortunately, Van can only be administered intravenously for systemic infections since its physico-chemical properties limit its permeability through intestinal epithelium. In this work we designed and surface-engineered SNPs to encapsulate and improve the permeability of Van. We successfully synthesized SNPs of different pore sizes and morphology and surface-modified their charge and polarity, and tested their impact on the release and permeation behaviour of loaded Van. Van-loaded SNPs showed high loading and a controlled release behaviour of Van compared to pure Van. Van-loaded SNPs exhibited significant enhancement of Van permeability through an epithelial cell monolayer, with

Van permeability enhancement dependent on the SNPs pore sizes and morphologies as well as their surface chemistry. Although the Van-loaded SNPs showed substantial improvement of Van permeation in the Caco-2 cell model, with high  $P_{app}$  values compared to pure Van, future work must conduct these permeability experiments in animal models to see whether this improvement is translatable *in vivo*. Furthermore, studies to decipher the exact mechanisms that SNPs use to increase the permeation of Van across Caco-2 cell monolayers are needed.

## Author contributions

John Ndayishimiye: conceptualization, methodology, visualization, data curation, software, investigation, writing, original draft, review & editing. Yuxue Cao: methodology, reviewing & editing. Tushar Kumeria: supervision, conceptualization, writing – review & editing. Mark A. T. Blaskovich: supervision, conceptualization, writing – review & editing. James Robert Falconer: supervision, conceptualization, writing – review & editing. Amirali Popat: supervision, conceptualization, writing – review & editing.

## Conflicts of interest

There are no conflicts of interests to declare.

## Acknowledgements

J. N. holds an Australian Government Research Scholarship and research funding from The University of Queensland. Y. C. acknowledges support from a University of Queensland post-graduate scholarship. A. P. acknowledges financial support from National Health and Medical Research Council for the Early Career (GNT1071796) and Career Development Fellowship (GNT1146627). T. K. acknowledges financial support from National Health and Medical Research Council (NHMRC) for the Career Development Fellowship (GNT1143296) and Australian Research Council (ARC) for the Discovery Fellowship (DP200102723). The authors acknowledge the support from the Australian Microscopy and Microanalysis Research Facility at the Centre for Microscopy and Microanalysis, the University of Queensland. Also, this work was performed in part at the Queensland node of the Australian National Fabrication Facility, a company established under the National Collaborative Research Infrastructure Strategy to provide nano- and micro-fabrication facilities for Australia's researchers.

## References

- 1 J. O'Neill, *Tackling drug-resistant infections globally: final report and recommendations (The Review on Antimicrobial Resistance)*, 2016.
- 2 S. Y. Tong, J. S. Davis, E. Eichenberger, T. L. Holland and V. G. Fowler, *Clin. Microbiol. Rev.*, 2015, **28**, 603–661.



- 3 A. Simon, M. L. A. Moreira, I. F. d. J. B. Costa, V. P. de Sousa, C. R. Rodrigues, T. Sisnande, F. A. do Carmo, I. C. R. Leal, K. R. N. Dos Santos and L. C. R. P. da Silva, *Nanotechnology*, 2020, **31**, 375101.
- 4 R. C. Moellering Jr, *J. Antimicrob. Chemother.*, 2012, **67**, 4–11.
- 5 I. M. Gould, M. Z. David, S. Esposito, J. Garau, G. Lina, T. Mazzei and G. Peters, *Int. J. Antimicrob. Agents*, 2012, **39**, 96–104.
- 6 A. Schilling, E. Neuner and S. J. Rehm, *Cleavel. Clin. J. Med.*, 2011, **78**, 465–471.
- 7 J. F. Mohr and B. E. Murray, *Clin. Infect. Dis.*, 2007, **44**, 1536–1542.
- 8 Y. Yang, M. V. McBride, K. A. Rodvold, F. Tverdek, A. M. Trese, J. Hennenfent, G. Schiff, B. L. Lambert and G. T. Schumock, *Am. J. Health-Syst. Pharm.*, 2010, **67**, 1017–1024.
- 9 P. E. Reynolds, *Eur. J. Clin. Microbiol. Infect. Dis.*, 1989, **8**, 943–950.
- 10 S. Patel, C. V. Preuss and F. Bernice, 2020, <https://pubmed.ncbi.nlm.nih.gov/29083794/>.
- 11 J. Ndayishimiye, A. Popat, M. Blaskovich and J. R. Falconer, *J. Controlled Release*, 2020, **324**, 728–749.
- 12 R. Fekety, J. Silva, C. Kauffman, B. Buggy and H. G. Deery, *Am. J. Med.*, 1989, **86**, 15–19.
- 13 J. Silva, D. Batts, R. Fekety, J. Plouffe, G. Rifkin and I. Baird, *Am. J. Med.*, 1981, **71**, 815–822.
- 14 Vancomycin hydrochloride, <https://pubchem.ncbi.nlm.nih.gov/compound/Vancomycin-hydrochloride>, accessed on December 3, 2020, 2020.
- 15 C. A. Lipinski, *Drug Discovery Today: Technol.*, 2004, **1**, 337–341.
- 16 C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, *Adv. Drug Delivery Rev.*, 1997, **23**, 3–25.
- 17 Vancomycin hydrochloride [https://www.chemicalbook.com/ChemicalProductProperty\\_EN\\_CB8117577.htm](https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8117577.htm), accessed on December 3, 2020, 2020.
- 18 J. M. Cyriac and E. James, *J. Pharmacol. Pharmacother.*, 2014, **5**, 83.
- 19 A. J. Kaasch, G. Fätkenheuer, R. Prinz-Langenohl, U. Paulus, M. Hellmich, V. Weiß, N. Jung, S. Rieg, W. V. Kern and H. Seifert, *Trials*, 2015, **16**, 450.
- 20 J. McLennon and M. A. Rogers, *J. Adv. Nurs.*, 2019, **75**, 30–42.
- 21 C. J. Sokolowski, J. A. Giovannitti and S. G. Boynes, *Dent. Clin.*, 2010, **54**, 731–744.
- 22 S. Sivagnanam and D. Deleu, *Crit. Care*, 2002, **7**, 1–3.
- 23 M. P. Wilhelm, *Mayo Clin. Proc.*, 1991, **66**, 1165–1170.
- 24 C. Liu, Y. Kou, X. Zhang, H. Cheng, X. Chen and S. Mao, *Expert Opin. Drug Delivery*, 2018, **15**, 223–233.
- 25 D. J. Drucker, *Nat. Rev. Drug Discovery*, 2020, **19**, 277–289.
- 26 E. M. Pridgen, F. Alexis and O. C. Farokhzad, *Expert Opin. Drug Delivery*, 2015, **12**, 1459–1473.
- 27 A. J. Almeida and E. Souto, *Adv. Drug Delivery Rev.*, 2007, **59**, 478–490.
- 28 M. Liu, J. Zhang, W. Shan and Y. Huang, *Asian J. Pharm. Sci.*, 2015, **10**, 275–282.
- 29 S. Maher, D. J. Brayden, L. Casettari and L. Illum, *Pharmaceutics*, 2019, **11**, 41.
- 30 N. G. Lamson, A. Berger, K. C. Fein and K. A. Whitehead, *Nat. Biomed. Eng.*, 2020, **4**, 84–96.
- 31 L. Wright, P. Joyce, T. J. Barnes, R. Lundmark, C. A. Bergström, M. Hubert and C. A. Prestidge, *J. Pharmaceut. Sci.*, 2020, **110**(1), 217–227.
- 32 M. M. Abeer, P. Rewatkar, Z. Qu, M. Talekar, F. Kleitz, R. Schmid, M. Lindén, T. Kumeria and A. Popat, *J. Controlled Release*, 2020, **326**, 544–555.
- 33 M.-C. Desjonqueres and D. Spanjaard, *Concepts in surface physics*, Springer Science & Business Media, 2012.
- 34 J. Kurczewska, P. Sawicka, M. Ratajczak, M. Gajęcka and G. Schroeder, *Int. J. Pharm.*, 2015, **486**, 226–231.
- 35 Z. Gounani, M. A. Asadollahi, J. N. Pedersen, J. Lyngsø, J. S. Pedersen, A. Arpanaei and R. L. Meyer, *Colloids Surf., B*, 2019, **175**, 498–508.
- 36 X. Zhou, W. Weng, B. Chen, W. Feng, W. Wang, W. Nie, L. Chen, X. Mo, J. Su and C. He, *J. Mater. Chem. B*, 2018, **6**, 740–752.
- 37 G. Qi, L. Li, F. Yu and H. Wang, *ACS Appl. Mater. Interfaces*, 2013, **5**, 10874–10881.
- 38 N. Hao, L. Li and F. Tang, *Int. Mater. Rev.*, 2017, **62**, 57–77.
- 39 J. Florek, R. Caillard and F. Kleitz, *Nanoscale*, 2017, **9**, 15252–15277.
- 40 C. Xu, C. Lei and C. Yu, *Front. Chem.*, 2019, **7**, 290.
- 41 M. Vallet-Regí, F. Balas, M. Colilla and M. Manzano, *Prog. Solid State Chem.*, 2008, **36**, 163–191.
- 42 I. Izquierdo-Barba, E. Sousa, J. C. Doadrio, A. L. Doadrio, J. P. Pariente, A. Martínez, F. Babonneau and M. Vallet-Regí, *J. Sol-Gel Sci. Technol.*, 2009, **50**, 421–429.
- 43 J. Zhang, S. Karmakar, M. Yu, N. Mitter, J. Zou and C. Yu, *Small*, 2014, **10**, 5068–5076.
- 44 X. Hong, X. Zhong, G. Du, Y. Hou, Y. Zhang, Z. Zhang, T. Gong, L. Zhang and X. Sun, *Sci. Adv.*, 2020, **6**, eaaz4462.
- 45 C. G. Bavnhoj, M. M. Knopp, C. M. Madsen and K. Löbmann, *Int. J. Pharm.: X*, 2019, **1**, 100008.
- 46 C. Bharti, U. Nagaich, A. K. Pal and N. Gulati, *Int. J. Pharm. Invest.*, 2015, **5**, 124–133.
- 47 E. Fröhlich, *Int. J. Nanomed.*, 2012, **7**, 5577–5591.
- 48 C. Dombu, R. Carpentier and D. Betbeder, *Biomaterials*, 2012, **33**, 9117–9126.
- 49 E. Blanco, H. Shen and M. Ferrari, *Nat. Biotechnol.*, 2015, **33**, 941–951.
- 50 M. Barisik, S. Atalay, A. Beskok and S. Qian, *J. Phys. Chem. C*, 2014, **118**, 1836–1842.
- 51 R. Cornu, C. Chrétien, Y. Pellequer, H. Martin and A. Béduneau, *Arch. Toxicol.*, 2020, **94**, 1191–1202.
- 52 H. Baghirova, D. Karaman, T. Viitala, A. Duchanoy, Y.-R. Lou, V. Mamaeva, E. Pryazhnikov, L. Khiroug, C. de Lange Davies, C. Sahlgren and J. M. Rosenholm, *PLoS One*, 2016, **11**, e0160705.
- 53 X. Tan, N. Yin, Z. Liu, R. Sun, J. Gou, T. Yin, Y. Zhang, H. He and X. Tang, *Mol. Pharmaceutics*, 2020, **17**, 3177–3191.

- 54 J. Leal, H. D. Smyth and D. Ghosh, *Int. J. Pharm.*, 2017, **532**, 555–572.
- 55 Z. Chaudhary, G. M. Khan, M. M. Abeer, N. Pujara, B. W.-C. Tse, M. A. McGuckin, A. Popat and T. Kumeria, *Biomater. Sci.*, 2019, **7**, 5002–5015.
- 56 E. Juère, G. Del Favero, F. Masse, D. Marko, A. Popat, J. Florek, R. Caillard and F. Kleitz, *Eur. J. Pharm. Biopharm.*, 2020, **151**, 171–180.
- 57 Y. Niu, M. Yu, A. Meka, Y. Liu, J. Zhang, Y. Yang and C. Yu, *J. Mater. Chem. B*, 2016, **4**, 212–219.
- 58 D. Sriramulu, E. L. Reed, M. Annamalai, T. V. Venkatesan and S. Valiyaveetil, *Sci. Rep.*, 2016, **6**, 1–10.
- 59 M. Lopes, N. Shrestha, A. Correia, M.-A. Shahbazi, B. Sarmento, J. Hirvonen, F. Veiga, R. Seiça, A. Ribeiro and H. A. Santos, *J. Controlled Release*, 2016, **232**, 29–41.
- 60 M. J. de Jesús Valle, F. G. López and A. S. Navarro, *J. Pharm. Biomed. Anal.*, 2008, **48**, 835–839.
- 61 M. Usman and G. Hempel, *SpringerPlus*, 2016, **5**, 124.
- 62 G. Kigen and G. Edwards, *BMC Pharmacol. Toxicol.*, 2017, **18**, 20.
- 63 P. Artursson, *J. Pharm. Sci.*, 1990, **79**, 476–482.
- 64 I. Hubatsch, E. G. Ragnarsson and P. Artursson, *Nat. Protoc.*, 2007, **2**, 2111.
- 65 M. Bouchoucha, M.-F. Cote, R. C. Gaudreault, M. A. Fortin and F. Kleitz, *Chem. Mater.*, 2016, **28**, 4243–4258.
- 66 N. S. Zaharudin, E. D. Mohamed Isa, H. Ahmad, M. B. Abdul Rahman and K. Jumbri, *J. Saudi Chem. Soc.*, 2020, **24**, 289–302.
- 67 K. Möller, J. Kobler and T. Bein, *Adv. Funct. Mater.*, 2007, **17**, 605–612.
- 68 E. Juère, J. Florek, M. Bouchoucha, S. Jambhrunkar, K. Y. Wong, A. Popat and F. Kleitz, *Mol. Pharmacol.*, 2017, **14**, 4431–4441.
- 69 T. Prasad, S. Halder and S. S. Dhar, *Mater. Today: Proc.*, 2020, **22**, 1669–1675.
- 70 X. Lv, L. Zhang, F. Xing and H. Lin, *Microporous Mesoporous Mater.*, 2016, **225**, 238–244.
- 71 E. Juère, R. Caillard and F. Kleitz, *Microporous Mesoporous Mater.*, 2020, **306**, 110482.
- 72 T. Ji, C. Ma, L. Brisbin, L. Mu, C. G. Robertson, Y. Dong and J. Zhu, *Appl. Surf. Sci.*, 2017, **399**, 565–572.
- 73 R. P. Bagwe, L. R. Hilliard and W. Tan, *Langmuir*, 2006, **22**, 4357–4362.
- 74 S. Bhattacharjee, *J. Controlled Release*, 2016, **235**, 337–351.
- 75 E. Juère, G. Del Favero, F. Masse, D. Marko, A. Popat, J. Florek, R. Caillard and F. Kleitz, *Eur. J. Pharm. Biopharm.*, 2020, **151**, 171–180.
- 76 M. Guo, Q. Liu, S. Lu, R. Han, K. Fu, C. Song, N. Ji, X. Lu, D. Ma and C. Liu, *Langmuir*, 2020, **36**, 11528–11537.
- 77 M. Bouchoucha, M.-F. Côté, R. C. Gaudreault, M.-A. Fortin and F. Kleitz, *Chem. Mater.*, 2016, **28**, 4243–4258.
- 78 M. Thommes, K. Kaneko, A. V. Neimark, J. P. Olivier, F. Rodriguez-Reinoso, J. Rouquerol and K. S. W. Sing, *Pure Appl. Chem.*, 2015, **87**, 1051–1069.
- 79 N. I. Vazquez, Z. Gonzalez, B. Ferrari and Y. Castro, *Bol. Soc. Esp. Ceram. Vidrio*, 2017, **56**, 139–145.
- 80 A. Yildirim, E. Ozgur and M. Bayindir, *J. Mater. Chem. B*, 2013, **1**, 1909–1920.
- 81 M. Mousavi and E. Fini, *ACS Sustainable Chem. Eng.*, 2020, **8**, 3231–3240.
- 82 Y. Zhao, Y. Wang, F. Ran, Y. Cui, C. Liu, Q. Zhao, Y. Gao, D. Wang and S. Wang, *Sci. Rep.*, 2017, **7**, 4131.
- 83 J. H. Park, S.-D. Baek, J. I. Cho, J. Y. Yoo, S.-Y. Yoon, S. Kim, S. Lee, Y. S. Kim and J.-M. Myoung, *Composites, Part B*, 2019, **175**, 107188.
- 84 M. Castellano, E. Marsano, A. Turturro and L. Conzatti, *Adsorption*, 2012, **18**, 307–320.
- 85 J. Seo and L. P. Lee, *Sens. Actuators, B*, 2006, **119**, 192–198.
- 86 H. Y. Erbil, G. McHale and M. Newton, *Langmuir*, 2002, **18**, 2636–2641.
- 87 E. Vargha-Butler, S. Sveinsson and Z. Policova, *Colloids Surf.*, 1991, **58**, 271–286.
- 88 M. H. Engelhard, T. C. Droubay and Y. Du, in *Encyclopedia of Spectroscopy and Spectrometry*, ed. J. C. Lindon, G. E. Tranter and D. W. Koppenaal, Academic Press, Oxford, 3rd edn, 2017, pp. 716–724, DOI: 10.1016/B978-0-12-409547-2.12102-X.
- 89 O. Sublemontier, C. Nicolas, D. Aureau, M. Patanen, H. Kintz, X. Liu, M.-A. Gaveau, J.-L. Le Garrec, E. Robert, F.-A. Barreda, A. Etcheberry, C. Reynaud, J. B. Mitchell and C. Miron, *J. Phys. Chem. Lett.*, 2014, **5**, 3399–3403.
- 90 A. G. Shard, *Surf. Interface Anal.*, 2014, **46**, 175–185.
- 91 J. C. Doadrio, E. M. Sousa, I. Izquierdo-Barba, A. L. Doadrio, J. Perez-Pariante and M. Vallet-Regí, *J. Mater. Chem. B*, 2006, **16**, 462–466.
- 92 R. P. Ralph, *Rev. Infect. Dis.*, 1981, **3**, S205–S209.
- 93 Y. Perrie and T. Rades, *FASTtrack Pharmaceuticals: Drug Delivery and Targeting*, Pharmaceutical Press, 2012.
- 94 E. I. Nielsen, O. Cars and L. E. Friberg, *Antimicrob. Agents Chemother.*, 2011, **55**, 4619–4630.
- 95 S. Hussain, J. Joo, J. Kang, B. Kim, G. B. Braun, Z.-G. She, D. Kim, A. P. Mann, T. Mölder and T. Teesalu, *Nat. Biomed. Eng.*, 2018, **2**, 95–103.
- 96 D. Hassan, C. A. Omolo, R. Gannamani, A. Y. Waddad, C. Mocktar, S. Rambharose, N. Agrawal and T. Govender, *Int. J. Pharm.*, 2019, **558**, 143–156.
- 97 J. Ndayishimiye, A. Popat, T. Kumeria, M. A. T. Blaskovich and J. Robert Falconer, *Int. J. Pharm.*, 2021, **596**, 120240.
- 98 A. Raza, F. B. Sime, P. J. Cabot, J. A. Roberts, J. R. Falconer, T. Kumeria and A. Popat, *ACS Biomater. Sci. Eng.*, 2021, **7**, 1836–1853.
- 99 P. Artursson and J. Karlsson, *Biochem. Biophys. Res. Commun.*, 1991, **175**, 880–885.
- 100 C. A. Larregieu and L. Z. Benet, *AAPS J.*, 2013, **15**, 483–497.
- 101 I. J. Hidalgo, T. J. Raub and R. T. Borchardt, *Gastroenterology*, 1989, **96**, 736–749.
- 102 W. Du, Y. Fan, N. Zheng, B. He, L. Yuan, H. Zhang, X. Wang, J. Wang, X. Zhang and Q. Zhang, *Biomaterials*, 2013, **34**, 794–806.
- 103 M. Pinto, *Biol. Cell.*, 1983, **47**, 323–330.
- 104 N. Shrestha, F. Araújo, M.-A. Shahbazi, E. Mäkilä, M. J. Gomes, B. Herranz-Blanco, R. Lindgren, S. Granroth,

- E. Kukk, J. Salonen, J. Hirvonen, B. Sarmiento and H. A. Santos, *Adv. Funct. Mater.*, 2016, **26**, 3405–3416.
- 105 N. N. Salama, N. D. Eddington and A. Fasano, *Tight Junctions*, Springer US, Boston, MA, 2006, pp. 206–219, DOI: 10.1007/0-387-36673-3\_15.
- 106 P. Artursson and S. D. Knight, *Science*, 2015, **347**, 716–717.
- 107 L. L. Mitic, C. M. V. Itallie and J. M. Anderson, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 2000, **279**, G250–G254.
- 108 S. Mendiratta, M. Hussein, H. A. Nasser and A. A. A. Ali, *Part. Part. Syst. Charact.*, 2019, **36**, 1900195.
- 109 C. Saraiva, C. Praça, R. Ferreira, T. Santos, L. Ferreira and L. Bernardino, *J. Controlled Release*, 2016, **235**, 34–47.
- 110 Y. Wang, C. Pi, X. Feng, Y. Hou, L. Zhao and Y. Wei, *Int. J. Nanomed.*, 2020, **15**, 6295.
- 111 V. Selvarajan, S. Obuobi and P. L. R. Ee, *Front. Chem.*, 2020, **8**, 602.
- 112 N. G. Lamson, G. Cusimano, K. Suri, A. Zhang and K. A. Whitehead, *Mol. Pharmaceutics*, 2016, **13**, 578–585.
- 113 K. Whitehead, N. Karr and S. Mitragotri, *Pharm. Res.*, 2008, **25**, 1782–1788.